

SWISS BIOTECH DAY 2026

May 4-5, 2026
Congress Center Basel

Conference guide

Host and event manager:




Logistics and marketing partner:

bamconn

Conference program at a glance

Monday, May 4, 2026

08:00-09:45	Citeline pre-event (by invitation only)	<i>Room Osaka/Samarkand, level 3</i>	
09:30	Early bird badge pickup	<i>Entrance CCB, level 0</i>	
10:00-11:00	Swiss Biotech Association general assembly	<i>Room Singapore, level 2</i>	
11:00	Registration opens	<i>Entrance CCB, level 0</i>	
11:00-11:45	Media conference (media only)	<i>Room Mexico, level 2</i>	
11:00-18:45	Exhibition	<i>Hall 4.0, level 0 Foyer, level 2 p. 57</i>	
11:00-18:00	Global Village, mentoring booths, Swiss cluster booths	<i>Room San Francisco, level 3 pp. 24 + 64</i>	
11:00-18:45	Partnering	<i>Hall 4.1, level 1 p. 7</i>	
11:30-13:30	Lunch	<i>Hall 4.0, level 0 Foyer, level 2 Foyer, level 3 p. 7</i>	
12:30-14:00	Plenary session I	<i>Room Montreal, level 2 p. 9</i>	
14:00-15:00	Coffee break	<i>Hall 4.0, level 0 Foyer, level 2</i>	
Parallel tracks			
14:30-18:15 Panels & pitches <i>Room Delhi, level 0</i> p. 10	14:30-18:15 Panels & pitches <i>Room Kairo, level 0</i> p. 12	14:30-18:15 Panels & pitches <i>Room Shanghai 1+2, level 0</i> p. 14	14:30-18:15 Panels & pitches <i>Room Shanghai 3+4, level 0</i> p. 16
14:30-15:15 Pitch digital chapter p. 10	14:30-15:15 Panel 1 - Clario p. 12	14:30-15:15 Panel 2 - Deloitte p. 14	14:30-15:15 Panel 3 - KPMG p. 16
15:30-16:15 Panel 4 - SOPHiA Genetics p. 10	15:30-16:15 Panel - Lonza p. 12	15:30-16:15 Panel 5 - Tibio p. 14	15:30-16:15 Panel 6 - Swiss- Japanese p. 16
16:15-17:00 Poster presentations			<i>Hall 4.1, level 1 Foyer, level 3 p. 66</i>
16:30-17:15 Panel 7 - Citeline p. 11	16:30-17:15 Panel 8 - talent chapter p. 13	16:30-17:15 Panel 9 - IQVIA / PharmaBiome p. 15	16:30-18:15 Pitch - Emerging Swiss biotech champions p. 17
17:30-18:15 Panel 10 - Zühlke p. 11	17:30-18:15 Panel 11 - Cetacea / Metronomia p. 13	17:30-18:15 Panel 12 - Cohesion Bureau p. 15	
18:00-18:45	International reception of the Global Village	<i>San Francisco, level 3 p. 29</i>	
18:45-21:00	Evening reception	<i>Hall 4.0, level 0 Foyer, level 2 Foyer, level 3</i>	



Sunday, May 3, 2026




17:30-20:30

Welcome reception

Markthalle Basel



Kindly supported by



<p>14:30-16:30 Emerging bio-tech company presentations <i>Room Singapore, level 2</i> p. 18</p> 	<p>14:30-18:15 Clinical stage bio-tech company presentations <i>Room Montreal, level 2</i> p. 20</p> 	<p>14:30-18:15 Commercial stage company presentations <i>Room Sydney, level 2</i> p. 21</p> 	<p>14:30-18:00 Moderated networking tables <i>Room Rio, level 2</i> 22</p> <p>14:30-15:00 Table 1 - Adimab p. 22</p> <p>15:10-15:40 Table 2 - Clinigen p. 22</p> <p>15:50-16:20 Table 3 - Impag p. 23</p> <p>17:10-17:40 Table 4 - Sciensus p. 23</p>	<p>14:15-17:15 Global Village <i>Room Osaka/Sa-markand, level 3</i> 32</p> <p>14:15-15:00 Plenary session p. 32</p> <p>15:15-16:00 Panel p. 32</p> <p>16:15-17:15 Pitch p. 33</p>
<p>16:45-17:30 Pitch - Nucleate p. 19</p> <p>17:45-18:30 Pitch - Venture leader p. 19</p>				

Conference program at a glance

Tuesday, May 5, 2026

07:15	Registration opens	<i>Entrance CCB, level 0</i>		
07:45-16:30	Partnering	<i>Hall 4.1, level 1 p. 7</i>		
09:00-16:30	Exhibition	<i>Hall 4.0, level 0 Foyer, level 2 p. 57</i>		
09:00-15:30	Global Village, mentoring booths, Swiss cluster booths	<i>Room San Francisco, level 3 pp. 24 + 64</i>		
09:00-09:45	Panel discussions & pitching sessions			
	Panel 13 - Aesara <i>Room Delhi, level 0</i> p. 37	Panel 14 - PSI <i>Room Kairo, level 0</i> p. 40	Panel 15 - Obelysq <i>Room Shanghai 1+2, level 0</i> p. 43	
10:00-12:00	Plenary session II		<i>Room Montreal, level 2 p. 36</i>	
12:00-14:00	Lunch 	<i>Hall 4.0, level 0 Foyer, level 2 Foyer, level 3 p. 7</i>		
Parallel tracks				
12:15-16:45	12:15-16:45	12:15-16:45	12:15-16:45	
Panels & pitches <i>Room Delhi, level 0</i> p. 37	Panels & pitches <i>Room Kairo, level 0</i> p. 40	Panels & pitches <i>Room Shanghai 1+2, level 0</i> p. 43	Panels & pitches <i>Room Shanghai 3+4, level 0</i> p. 46	
12:15-13:00	12:15-13:00	12:15-13:00	12:15-13:00	
Pitch - industrial biotech p. 37	Panel 17 - BiomedVC p. 40	Pitch - lab automation p. 43	Panel 18 - Swiss Biotech Ass. p. 46	
13:00-13:45	13:00-13:45	13:00-13:45	13:00-13:45	
Panel 19 - BlancLabo p. 38	Panel 20 - CSL p. 41	Panel 21 - diagnostics p. 44	Panel 22 - WuXi App- Tec p. 47	
14:00-14:45	14:00-14:45	14:00-14:45	14:00-14:45	
Panel 23 - Hombur- ger/Hoffmann p. 38	Panel 24 - Schellen- berg Wittmer p. 41	Panel 25 - Livinovea p. 44	Panel 26 - Molecular Partners p. 47	
14:45-15:30	Poster presentations		<i>Hall 4.1, level 1 Foyer, level 3 p. 66</i>	
15:00-15:45	15:00-15:45	15:00-15:45	15:00-15:45	
Panel 27 - Verdeya p. 39	Panel 28 - WuXi XDC p. 42	Panel 29 - Solvias p. 45	Panel 30 - Siemens p. 48	
16:00-16:45	16:00-16:45	16:00-16:45	16:00-16:45	
Panel 31 - Baker McKenzie p. 39	Panel 32 - Syneos Health p. 42	Panel 33 - CinnaGen p. 45	Panel 34 - Viridis- Group p. 48	
15:30-16:30	Marketplace of the Global Village		<i>Room San Francisco, level 3 p. 29</i>	
16:45-18:30	Farewell reception		<i>Hall 4.0, level 0 Foyer, level 2</i>	



Pitch - Curie.Bio

*Room Shanghai
3+4, level 0* p. 46

Panel 16 - FGK

Room Singapore, level 2 p. 49

12:30-16:45
Emerging biotech company presentations
Room Singapore, level 2 p. 50



12:30-15:00
Clinical stage biotech company presentations
Room Montreal, level 2 p. 51



15:15-16:00
Investor pitch - Creadd p.51

12:30-16:45
Commercial stage company presentations
Room Sydney, level 2 p. 52



12:10-15:20
Moderated net-working tables
Room Rio, level 2 53

12:10-12:40
Table 5 - Dinamiqs p. 53

12:50-13:20
Table 6 - Clinilabs p. 53

Room Mexico, lev. 2:
14:50-15:20
Table 7 - DataArt p. 53

12:15-15:15
Global Village
Room Osaka/Sa-markand, level 3 34

12:15-13:00
Panel p. 34

13:15-14:15
Pitch p. 34

14:30-15:15
Panel p. 35

Welcome reception

Welcome reception

Markthalle Basel

Sunday, May 3, 2026 | 17:30 - 20:30 | Markthalle Basel, Steinentorberg 20

The Swiss Biotech Day will once again provide a platform in Basel for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.

This inaugural gathering provides a prime networking opportunity, allowing attendees to connect and engage with peers before the event officially starts. Join more than 1,500 other participants who have signed up for this reception for an aperitif and an informal fun networking evening in anticipation of the lively days ahead.

Kindly supported by **Basel**⁺
basel.ch

**THIS IS
BASEL**

BASELLAND
www.basel.ch

Cooley



Housekeeping notes

Food will be served at the times and locations listed below. Beverages are available in all areas throughout the event.

Monday, May 4, 2026

Level 0	Level 2	Level 3
11:30 - 13:30 Lunch	11:30 - 13:30 Lunch	11:30 - 13:30 Lunch
		18:00 - 18:45 International reception
18:45 - 21:00 Evening reception	18:45 - 21:00 Evening reception	18:45 - 21:00 Evening reception

Tuesday, May 5, 2026

Level 0	Level 2	Level 3
12:00 - 14:00 Lunch <small>supported by</small> Acumetis	12:00 - 14:00 Lunch <small>supported by</small> Acumetis	12:00 - 14:00 Lunch <small>supported by</small> Acumetis
		15:30 - 16:30 Global Village market place
16:45 - 18:30 Farewell reception	16:45 - 18:30 Farewell reception	

You will find a **barista station at booth 61 in Hall 4.0** on level 0 for your much-needed daily dose of caffeine, kindly supported by



Pre-scheduled one-to-one meetings

Please check your individual meeting schedule for times and locations of your confirmed meetings. Need help? Please see the partnering help desk on level 1.

supported by **BeOne**



Free WiFi - kindly supported by **CITELINE**
a norstella company
 SSID: Free Messe Basel
 Login via SMS
 (one Login per device)



X

#swissbiotechday



LinkedIn

#swissbiotechday

SWISS BIOTECH™

Collaborate with us and use the power of our networking platforms

Save the date!



Swiss Biotech Day: April 26-27, 2027

For international networking at one of the leading global biotech conferences, with thousands of guests



Boosting global visibility

By promoting biotechs in the Swiss Biotech Directory, by disseminating their news, and with success stories



Financing and partnering

By connecting Swiss R&D biotech companies with global investors and industry partners on Swiss Biotech Ventures



Finding talent internationally

By matching Swiss job opportunities and talents on Swiss Biotech Orbit



Foster international collaboration


By uniting foreign biotech clusters with the Swiss biotech ecosystem through our Global Village



Professional development and education

At the Swiss Biotech Association Academy offered by academic institutions & regular Swiss Biotech Insight meetings

Powered by



Plenary session

12:30-14:00 Plenary session I**Room Montreal, level 2**

Moderation: **Monika Jones**

12:30 Welcome local host

Kaspar Sutter, Head of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt

12:35 Welcome organizer

Michael Altorfer, CEO, Swiss Biotech Association

12:45 Fireside session

Thomas Schinecker, CEO, Roche Group, and
Patrick Amstutz, President of the Swiss Biotech Association

13:20 Business development panel

Host: **Frances Stocks Allen**, Partner Life Sciences, Cooley

Panelists:

Richard Girling, Partner Life Sciences Investment Banking, Centerview

Jason Radford, Senior Vice President Strategic Partnerships, BeOne Medicines

Dragan Grabulovski, Chief Executive Officer, Araris

13:45 Swissmedic

Vincenza Trivigno, Executive Director, Swissmedic

Panels & pitches

Presented by  Swiss Biotech Association

14:30-15:15 Pitch

Room Delhi, level 0

Digital and health technologies chapter: AI-driven breakthroughs from target to therapy

This pitching session brings together a new wave of startups leveraging artificial intelligence, digital twins, and advanced biologics to transform therapeutics development. From target identification and validation to therapeutic design and clinical acceleration, these companies showcase how data-driven approaches and novel platforms are increasing speed, precision, and scalability. Covering applications spanning from oncology to aging and beyond, the session highlights how integrated digital and biological innovations are reshaping the future of healthcare.

Moderation: **Annamaria Kauzlaric**, Head of digital and health technologies chapter, Swiss Biotech Association

Jury: **Philippe Menu**, Chief Medical Officer & Chief Product Officer SOPHiA Genetics | **Sandra von Meier**, Head of Business Development Life Science, Terra Quantum | **Maria Escala-Garcia**, Investment Associate, VI Partners

14:30 Introduction

14:35 TwinEdge Bioscience

14:55 Glass Medical AI

14:40 Lemna Bio

15:00 Precise Health

14:45 Fy Cappa Biologics

15:05 Sydra

14:50 ALP AI

15:10 Voting and closing remarks

Presented by  SOPHiA GENETICS

15:30-16:15 Panel 4

Room Delhi, level 0

Liquid biopsy at a tipping point in precision oncology

Liquid biopsy is reaching a critical inflection point in precision oncology, yet its full potential remains largely untapped.

This panel explores how decentralized models, AI-powered analytics, and ecosystem-level collaborations are driving broader liquid biopsy adoption. Experts will trace the evolution of MSK-ACCESS® powered with SOPHiA DDM™ from an innovative in-house test to a globally scalable solution and examine how the shared vision between SOPHiA GENETICS and MSK has the potential to transform the future of precision oncology.

Moderation: **Philippe Menu**, Chief Medical Officer & Chief Product Officer, SOPHiA Genetics

Panelists:

Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca

Elena Guerini Rocco, Director of the Oncology Genetics Unit, Istituto Europeo di Oncologia

Panels & pitches

Presented by  a remsella company

16:30-17:15 Panel 7

Room Delhi, level 0

What's next in R&D, innovation, and clinical development?

AI and emerging clinical trends are reshaping the R&D landscape at unprecedented speed. This panel discussion will explore shifting scientific priorities, data-driven decision-making, and the evolution of trial design, offering clear perspective into how the next generation of therapies will be discovered, developed, and delivered.

Moderation: **Daniel Chancellor**, VP of Thought Leadership, Norstellia

Panelists:

Martin Svorc, Director, Neurology & Immunology, Business Development & AI Strategy and Enablement Lead, Merck

Benjamin August, Senior Director, Search & Evaluation – Research & Technologies, Daiichi Sankyo

Samir Ounzain, CEO and Co-Founder, Haya Therapeutics

Michael Pitzner, Group General Counsel, Senior Vice President Legal and Business Development, Molecular Partners

Presented by



17:30-18:15 Panel 10

Room Delhi, level 0

AI-powered pharma R&D, end-to-end: Connecting data, labs, and decision

AI is embedded across pharma R&D, yet many programmes still stall at pilot stage. For life sciences leaders, the question is no longer whether to use AI, but how to turn it into sustained impact. Real progress depends on connecting how data is generated, shared, and reused across the value chain. This panel explores how to link labs, data, and decisions at scale – from autonomous labs to clinical and real-world evidence – and shares candid lessons on what works, where friction remains, and what must change to deliver measurable business value.

Moderation: **Thibault Geoui**, Thought Leader in Data & AI for the Pharma & Biotech Industry, Zühlke

Panelists:

Ashiq H. Khan, Chief Business Officer, Evotec

Constantin Landers, Life Sciences Lead D-A-CH, Nvidia

Gerit Brandenburg, Senior Director of AI and Automation in Drug Discovery, Merck

Le (Muller) Mu, MLOps lead, Computational Sciences Center of Excellence, Roche

Panels & pitches

Presented by


14:30-15:15 Panel 1
Room Kairo, level 0

Optimizing digital endpoint strategies for success

Selecting the right clinical trial endpoints is essential for achieving study scientific objectives, regulatory success, investor confidence and efficient trial execution. This panel discussion will explore best practices for determining the optimal strategy to meet these goals, while balancing feasibility and cost. Attendees will also gain insight to selecting and overseeing a CRO partner effectively. Comprised of senior management from a CRO, biotech company, and an endpoint solutions vendor, the panel will provide diverse perspectives. Audience participation and Q&A will be encouraged.

Moderation: **Todd Rudo**, EVP, Chief Medical Officer, CLARIO

Panelists:

Florian Vogl, Chief Medical Officer

Lewis Cameron, CEO, Evestia Clinical CRO

John Ohrn, SVP, Global Partnerships, CLARIO

Chris Clendening, SVP Biotech Operations and Product Management, CLARIO

Presented by


15:30-16:15 Panel 4b
Room Kairo, level 0

Engineering success: How partnerships transform early biotech into fundable ventures

In today's increasingly complex and capital-intensive biotech landscape, early-stage companies face mounting pressure to demonstrate not only scientific innovation, but also a clear path to scalability, manufacturability, and commercial success. Strategic partnerships are emerging as a critical lever to bridge this gap—transforming promising science into investable opportunities.

This panel will explore how collaborations between biotech startups, CDMOs, and venture capital stakeholders can effectively de-risk early-stage innovation.

Moderation: **Zara Asgharpour**, Director External Innovation Integrated Biologics R&D, Lonza

Panelists:

Peter Droc, Head of Licensing, Lonza

Tristan Bepler, CEO, Open Protein AI

Klaus Orlinger, CSO, Valanx Biotech

Nikita Sharma, Principal, Ridgeline - a Versant incubator

Panels & pitches

Presented by **KennedyFitch**

16:30-17:15 Panel 8

Room Kairo, level 0

Your pipeline isn't the bottleneck - your organization is: Learning velocity as the hidden value driver in Swiss biotech

In today's biotech landscape, capital is scarce and pipelines are strong – yet many companies struggle to deliver.

The difference increasingly lies in organizational tenacity: the ability to adapt, reskill and execute under continuous pressure.

This panel challenges where true bottlenecks sit and explores how learning velocity determines which companies turn funding into sustainable value.

Moderation: **Eva Perez Casesmeiro**, Head DDIT US&I Marketing & Customer Engagement, Novartis

Panelists:

Sarah Holmes-Klotz, CHRO, Santhera

Melanie Rolli, Former Group CEO, Boardmember & Advisor, Helsinn

Alan Rankin, CPO, Moderna

Annett Zippel, Partner & People Advisor, KennedyFitch

Presented by



METRONOMIA



17:30-18:15 Panel 11

Room Kairo, level 0

Beyond the database: Turning clinical trial data into strategic advantage

Clinical trial data is more than a regulatory deliverable — it is a long-term strategic asset. This panel explores how early- and mid-stage biotech companies can move beyond database lock and build data infrastructures that enable scientific insight, cross-trial integration, and commercial leverage. Learn how structured data governance strengthens decision-making, accelerates partnerships, and directly impacts company valuation in competitive markets.

Moderation: **Cornelia Baumgartner**, Owner and Founder, Cetacea Clinical

Panelists:

Ulf Grawunder, CEO, T-CURX

Elisabeth Steiger, Senior Director Clinical Data Management, Metronomia

Royden James, Chief Product Officer, Viedoc

Günter Fingerle-Rowson, Chief Medical Officer, Tubulis

Panels & pitches

Presented by **Deloitte.**

14:30-15:15 Panel 2

Room Shanghai 1+2, level 0

Engineering longevity: Where science, innovation and the future of health systems converge

Health and longevity are emerging as one of defining frontiers of health of the next decade. As populations age and chronic disease burdens rise, innovations in science and technology are reshaping how we understand – and potentially intervene in the biological processes that drive ageing. Breakthroughs in aging biology, AI-driven diagnostics, and preventive medicine are opening the door to interventions that could extend not just lifespan, but healthspan. How can pharmaceutical innovation, strategic capital, nutritional science, and technology platforms work together to translate advances in longevity science into scalable and sustainable health?

Moderation: **Andrea Feigl**, Senior Director, Health Financing Strategy, Deloitte

Panelists:

Alexandra Vallon-Eberhard, Senior Director, Global Strategy & Partnering, Roche

Anne Marije van Harten, Investment Director, Apollo Health Ventures

Ricardo Gaminha Pacheco, Head of Strategic Partnerships, Insilico Medicine

Presented by **TIBIO**


15:30-16:15 Panel 5

Room Shanghai 1+2, level 0

Bioremediation and beyond: Biotechnology for resilient soils and sustainable living

Soils face growing pressure from contamination and land use changes, yet biotechnology offers tools for their recovery. This panel unites experts from agrochemistry, biotech industry, and public sector to explore how environmental biotechnology and cleantech work in real-world contexts. Topics include biological remediation, innovation at the science-industry interface, and pathways toward sustainable soil management. The discussion addresses current limitations and future directions, connecting applied expertise with scientific perspectives to show how biotech drives environmental change.

Moderation: **Rita Di Martino**, Head of Biology, TIBIO

Panelists:

Anne-Laure Gassner, Scientific Project Leader, Federal Department of Defense, Civil Protection and Sport

Federica Torigino, Research Engineer, Casale

Michal Brylinski, Founder & CEO, Bionrec

Guillaume Boisard, Project Manager, TIBIO

Panels & pitches

Presented by 
16:30-17:15 Panel 9
Room Shanghai 1+2, level 0

From data to discovery: Shaping the future of microbiome therapeutics

Join us for a dynamic session featuring a panel discussion on the recent developments in the microbiome field. Experts, investors, and biotech leaders will explore key achievements, challenges, and success factors in microbiome-based therapies and especially how data are shaping the future of the field.

Moderation: **Tomas de Wouters**, CEO, PharmaBiome

Panelists:

Alan Harris, Senior VP Global R&D, Ferring Pharmaceuticals

Benjamin Hadida, CEO, Exeliom Biosciences

Mat Robinson, Senior VP Research, Microbiotica

Aurelio Arias, Director, IQVIA

Presented by


17:30-18:15 Panel 12
Room Shanghai 1+2, level 0

The art of the deal: Why some biotechs get it and others don't

The panel "The art of the deal: Why some biotechs get it and others don't" will examine how biotech fundraising and partnering decisions are actually made, looking at how subjects such as data quality, team credibility, market timing, and risk tolerance influence capital allocation from the perspectives of CEOs, VCs, potential partners and media.

Moderation: **Richard Jarvis**, Partner, Cohesion Bureau

Panelists:

Gabor Gyölvéshi, Principal, Novo Seeds

Cormac Sheridan, Senior biotech reporter

Karen Wagner, Managing Partner, Ysios

Panels & pitches

Presented by


14:30-15:15 Panel 3
Room Shanghai 3+4, , level 0

Beyond transactions: Building sustainable Swiss-China partnerships

As the biotechnology world embraces multipolarity, new bridges need to be built between countries to create value. China and Switzerland are two heavyweights in the global life sciences ecosystem. How could Swiss and Chinese companies use the strengths of each other to drive innovation and to establish a sustainable and mutually beneficial partnership model? Join our discussion with experienced cross-border biopharma bridge makers.

Moderation: **Peter Mozerov**, Senior Manager, KPMG

Panelists:

Kuno Gschwend, Deputy Head, Swiss Business Hub China, Embassy of Switzerland in China

Bettina Ernst, CEO, Bernina Bioinvest

Eric Adam, Chief Operating Officer, Haya Therapeutics

Henri de Vlam, Senior Business Development Manager, Chime Biologics

Peter Zeng, Managing Director, Zeyu Capital

Presented by


15:30-16:15 Panel 6
Room Shanghai 3+4, , level 0

The merits and challenges of Swiss-Japanese partnerships

This panel explores partnerships between Swiss biotech companies and Japanese pharmaceutical firms, focusing on key advantages, challenges, and cultural alignment. It will also examine alternatives to equity financing and share practical insights into structuring and sustaining successful cross-border collaborations.

Moderation: name can be found on our website

Panelists:

Dragan Grabulowski, CEO, Araris

Barbara Angehrn, CEO, Numab

Marc Gitzinger, CEO, BioVersys

Panels & pitches

Presented by  Swiss Biotech Association

16:30-18:15 Pitch

Room Shanghai 3+4, level 0

Future stars

Showcases a curated group of high-quality Swiss biotech companies developing innovative solutions across therapeutics, diagnostics, and enabling technologies. Each company will present its vision, science, and value proposition, followed by a live Q&A. The session offers investors, partners, and industry leaders early insight into the next wave of Swiss biotech innovation.

Moderation: **David Urech**, Vice President, Swiss Biotech Association
Bettina Ernst, Vice President, Swiss Biotech Association

Jury: **Luca Bolliger**
Markus Goebel
Patrick Burgermeister

Pitching companies:

16:38	Allegria Therapeutics	17:26	Interax
16:46	Aukera Therapeutics	17:34	MetaLead
16:54	ClearideBio Therapeutics	17:42	MyoPax
17:02	Immitra Bio	17:50	Nerai Bioscience
17:10	InkoCell	17:58	Phialogics
17:18	InkVivo Technologies	18:06	Seito Biologics

Find details about the panel discussions here... →










... and about the pitching sessions here →



Emerging biotech companies

Presented by **PUREOS**
BIOVENTURES

Time	Company	Room Singapore, level 2
14:30	Pureos Bioventures	
14:45	OphthaNova	
15:00	SwitchKine	
15:15	HemastaTx	
15:30	EvlaBio	
15:45	Humion	
16:00	Ultimate Medicine	

Moderation: **Dominik Escher**, Managing Partner, Pureos Bioventures
Anne Grahl, Investment Manager, Pureos Bioventures

Find details about the presenting companies here →



**16:45-17:30 Pitch****Room Singapore, level 2**

Nucleate Switzerland: Showcasing the future of life sciences

Nucleate Switzerland will host a dedicated pitch session featuring selected Activator teams, showcasing some of the most promising early-stage, science-driven startups emerging from academia. These teams will present their innovations to an international audience of investors, pharma leaders, and biotech experts, creating exciting opportunities for connection, collaboration, and future growth.

Nucleate brings a highly curated pipeline of science-driven startups alongside a globally recognized network. As a global nonprofit with centralized leadership and active chapters across Europe and the US, we connect emerging innovators with investors, industry leaders, and partners worldwide.

Moderation: **Ebru Topcu Barileva**, Co-Managing Director, Nucleate Switzerland

Jury: **Sarah Holland**, CBO, CDR Life & President, Swiss Healthcare Licensing Group
Anne Marije van Harten, Investment Director, Apollo Health Ventures

Pitching companies:

16:50	MutaDent	17:10	Versarys Bioscience
17:00	Talixeon Therapeutics	17:20	ZuriEV

**17:45-18:30 Pitch****Room Singapore, level 2**

Meet the Venture Leaders Biotech 2026

Meet the 2026 Swiss National Startup Team in Biotech before they embark on their exclusive roadshow to Boston!

Join us for an exciting evening as 10 of Switzerland's most promising biotech startups take the stage to pitch their breakthrough innovations. This is a unique opportunity to discover the companies shaping the future of biotech and connect with founders, investors, and ecosystem leaders.

The Venture Leaders Biotech program is organized by Venturelab and supported by the University of Basel, EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.

Moderation: **Jordi Montserrat**, Co-Founder and Managing Partner, Venturelab
Maurice Stäheli, Project Manager, Venturelab

Pitching companies:

17:45	Baio Labs	18:10	Immitra Bio
17:50	Baxiva	18:15	NanoZymeX
17:55	Biodelphis Tx	18:20	Translation-X
18:00	Bioscibex	18:25	UNOMR
18:05	GlioCART	18:30	Visienco

Clinical stage companies

Presented by

















Time	Company	Room Montreal, level 2
14:30	Celonic	
14:45	Topadur Pharma	
15:00	Oculis Operations	
15:15	Azafaros	
15:30	Genevant Sciences	
15:45	Light Chain Biosciences	
16:00	CanVirex	
16:15	EsoCap	
16:30	Break	
16:45	Basilea	
17:00	OM Pharma	
17:15	NovaGo Therapeutics	
17:30	AB2 Bio	
17:45	MetrioPharm	
18:00	Vaderis Therapeutics	

Moderation: **Georg Blaser**, VP of Biologics Development Center, Celonic Group

Commercial stage companies

Presented by **Lonza**

Time	Company	Room Sydney, level 2
14:30	Lonza	
14:45	Revvity	
15:00	Labcorp Holdings	
15:15	Parexel International	
15:30	PolyPeptide Group	
15:45	Oncodesign Services	
16:00	Cube Biotech	
16:15	Sartorius Stedim	
16:30	Break	
16:45	Vetter Pharma	
17:00	Santhera Pharmaceuticals	
17:15	Thermo Fisher Scientific	
17:30	KBI Biopharma	
17:45	INITS SMO	
18:00	Alphalyse	

Moderation: **Cristina Grigore**, Director Commercial Development, Integrated Biologics, Lonza

Moderated networking tables

Presented by  ADIMAB

14:30-15:00 Networking table 1

Room Rio, level 2

Challenges and solutions in discovery, generation, and characterization of multispecifics

There is an increasing understanding that monospecific antibodies are often insufficiently effective across all patients and/or indications. This has led to a growing interest in bispecific and multispecific modalities to target multiple signaling pathways and/or cell types. The goal of this roundtable will be to describe the current challenges in the discovery, generation, and characterization of bispecific and multispecific antibodies. We will furthermore discuss if the field is approaching any consensus on preferred formats and geometries, and how to arrive at the best molecule for a given application.

Moderation: **William Roach**, Senior Director of Technology Alliances, Adimab

Presented by  CLINIGEN

15:10-15:40 Networking table 2

Room Rio, level 2

Scaling from early research to clinical trials: What surprised you most?

An open conversation about the unexpected challenges biotechs encounter when moving from early research toward first-in-human and early-phase clinical development. Participants are invited to share real experiences – from CMC and manufacturing readiness to clinical supply timing, team coordination, and regulatory expectations – and explore how operational preparedness influences timelines and overall trial success.

Moderation: **Michelle Jung-Maltese**, Clinigen

Moderated networking tables

Presented by **impag**

15:50-16:20 Networking table 3

Room Rio, level 2

The right raw material at the right time: How specialized distributors shape the quality and speed of biotech innovation

The reliable sourcing and handling of chemical raw materials is one of the most underestimated factors in biotech innovation. This roundtable explores the strategic role specialized distributors play – from supply chain resilience, local warehousing and customs management, to formulation expertise, regulatory compliance and industrial-scale volume supply. With 100 years of distribution experience, deep supplier relationships and institutional knowledge, specialized distributors are more than middlemen – they are critical partners in bringing biotech innovation to life.

Moderation: **Markus Sierigk**, Head of Pharma, IMPAG

Presented by **Sciensus**
Fastest route to patients in Europe

17:10-17:40 Networking table 4

Room Rio, level 2

From molecule to companion: Building digital patient support in a regulated world

Sciensus will host a practical session exploring how digital patient support can become a scalable source of commercial value for biotech, improving adherence, generating real-world evidence and strengthening launch and lifecycle strategy.

Moderation: **Katie Duncalf**, Director Of Innovation & Market Strategy, Sciensus
Lucia Rüdlinger, Head of Regulatory Affairs, VIPS Representative Swiss
Pharma Association

Find details about the networking tables here →



Global Village

Presented by  Swiss Biotech Association

Supported by  SWITZERLAND GLOBAL ENTERPRISE 

Global Village

Room San Francisco, level 3

Welcome to the Global Village at the Swiss Biotech Day 2026 - The power of international collaboration

The Global Village, spearheaded by the **Swiss Biotech Association**, serves as a premier platform to foster international collaboration and networking within the biotech and life sciences industries. In partnership with leading Swiss organizations, it offers a continuous, year-round gateway for global biotech clusters to forge and deepen strategic, long-term partnerships within Switzerland's thriving biotech ecosystem.

The **Global Village mission** is centered around:

- **Connecting global life sciences hubs with Swiss biotech leaders**
Leverage the **international reception (p. 29)** and **marketplace (p. 29)** to meet and connect with international delegations, or visit them directly at their booths in the **Global Village exhibition area (p. 25)**.
- **Empowering international delegations**
Take part in the **bilateral roundtable discussions (p. 30)**, designed for international delegations seeking to build and strengthen long-term, sustainable business relationships and collaborations with key decision-makers in the Swiss biotech ecosystem.
- **Driving collaborative excellence**
Join the **Global Village stream (p. 32)**, including the **Global Village plenary session**, where we highlight the power of international collaboration, encourage the exchange of best practices, and foster joint initiatives that create mutual value for all stakeholders.

Since its inception in 2022, the Global Village has welcomed delegations from **all five continents**, underscoring its success in advancing global biotech collaboration.

This year, the Global Village is hosting a record number of **31 delegations**, and all Swiss Biotech Day participants are welcome to attend and actively contribute to the program.

Find further information about the Global Village here →



Delegation

Africa – booth GV21b

Participating companies:

Africa Collective, Biomine Health, Cape Bio, CSIR - Council for Scientific and Industrial Research, CureRoot, Department of Science, Technology and Innovation, Inqaba Biotec, Liqid Medical, OneBio, Ortho Design, Stellenbosch University, Technology Innovation Agency, TokaBio



Australia – booth GV17

Participating companies:

360biolabs, Accelagen, Avion CRO, Bentleys, CMAX Clinical Research, CPL, Crux Biolabs, Linear Clinical Research, Nucleus Network, Pharmsky Research (Australia)



Australian Government
Australian Trade and Investment Commission

Baden-Württemberg – booth GV7

Participating companies:

Baden-Württemberg International, BioRN Network, Bimovis



Bavaria – booth GV8

Participating companies:

Bayern International, Invest in Bavaria, BioM, BSL Bioservice Scientific, Ethris, Fördergesellschaft IZB, Fraunhofer ITEM, Granzer Regulatory Consulting & Services, IMP, Labor LS, Laboratories Munich, leon-nanodrugs, Project Pharmaceuticals, Spark Microgravity, Staburo, TQ Therapeutics, Trophic Communications



Canada – booth GV14

Participating companies:

20/20 OptimEyes Technologies, 3DBiofibr, Access Innovation BioBridge, Atlantic BioCorp, BioAro, BioBox, Blue Ocean Technologies, CCRM, Copoly.ai, Cura Therapeutics, Diex Recherche, Eyam Health, Genaiz, InTheKnow PharmaSolutions, KreaMedica, Modulari-T, Molecular Forecaster, Ness Therapeutics, Pegasus Biotech Incorporated, PRiME – Next Generation Precision Medicine, Royalmount BioPharma Services, Sciences Cinq Prime/Five Prime Sciences, Scotiaderm, Sussex Research Laboratories, Trade Commissioner Service / Government of Canada, Voxcell Bioinnovation



Chile – booth GV6c

Participating companies:

CBT Sofofa Hub, Codebreaker, Embassy of Chile in Switzerland, Farmoquímica del Pacifico, Luyef Biotechnologies, Pewman Innovation, Phage Lab, ProChile. Synergia Bio



Global Village

Delegation

China – booth GV20

Participating companies:

ABclonal Technology, Biocytogen, Canton Biologics, LTZ Therapeutics, Medicilon, Porton Pharma Solutions, SBH China, Sphinx Scientific Laboratory (Tianjin), XtalPi



Emilia Romagna – booth GV25b

Participating companies:

Camera di Commercio Italiana per la Svizzera, Focalis, Promos, TPM



Estonia – booth GV21c

Participating companies:

Chemestmed, Enterprise Estonia, Estonian Embassy, Helmes, Metrosert Applied Research Center, Ministry of Foreign Affairs of Estonia, Selfdiagnostics, Tartu Biotechnology Park, TBD Pharmatech, vectiopep



Flanders – booth GV6b

Participating companies:



France – booth GV26

Participating companies:

Accueil - Apmonia therapeutics, Bioseb, Cell Environment, Cilcare, ICTA, Kimialys, LFB, PLL Therapeutics, Research Pieces, Servier



Greece – booth GV6a

Participating companies:

ABCureD, Critica Pharma, Nudge Care, Oncolipsy, Pharmassist, PKNM Solutions, Prinsus



Hong Kong – booth GV13

Participating companies:

Hong Kong-Shenzhen Innovation and Technology Park, InvestHK, OncoNex-Remunity, Quant Biomarkers, SunRegen Healthcare AG



India – booth GV10

Participating companies:

Aganitha AI, Aragen Bio, Ascelis Peptides, Clinixel, Cognizant, Neuland Laboratories, Nucelion Therapeutics, Pi Health Sciences, Sai Life, Zasya Life Sciences



Delegation

Italy – booth GV29b


Participating companies:
PerfeTTO network



Japan – booth GV19

Participating companies:

Asahi Kasei Pharma, Astellas, Daiichi Sankyo Europe, DeSC Healthcare, Eisai, iBody, Itochu Europe, Kissei Pharmaceutical, Maruho, Matrixome, NTT Data, Sekisui Chemical, Swiss Business Hub Japan, Tillotts Pharma, Veritas In Silico, Yokogawa



Latvia – booth GV24

Participating companies:

AI Invest Labs, Biosan, Capture Study, Cellbox Labs, Double Helix Technologies, Inpharmatis, Institute of Solid State Physics, Latvian Institute of Organic Synthesis, Latvian Office for Innovation and Technology, Lexu Care, Longgenesis, PrintyMed, University of Latvia



Lithuania – booth GV27

Participating companies:

Bious Labs, Expermentika, Fitodenta, LithuaniaBIO, Luko Laboratorija, Seqvision, VUGENE



Netherlands – booth GV18

Participating companies:

Dutch Embassy, Health Holland, iPsonics, RVO, Single Cell Discoveries, UMCG



Nordic Countries – booth GV16

Participating companies:

Acapo Onsagers, APNC, Atrogi, Aurlide, Berking Theranostics, Business Finland, Capsih, Collectricon, ChainPeptides, Curacell, Evogence Biologics, Genomill, Innosiamo, Invest in Skåne, Kinsea Lead Discovery, Life Science Nord, Mo:re, ModelMole, Medicon Valley Alliance, Neurometa, NorthX Biologics, Paras Biopharmaceuticals, SPARK Norway | UiO:Life Science, Sweden Bio, The Life Science Cluster, Vactech



North Carolina – booth GV23

Participating companies:

Aesara, Economic Development Partnership of North Carolina, iOrganbio, Jericho Sciences, Kymanox, Moon Pharma, Tanner Pharma Group, Teguar



Global Village

Delegation

North Rhine-Westphalia – booth GV25a



Participating companies:

BIO Clustermanagement NRW, BIO.NRW, Cellbox Solutions, Khanu, Lead Discovery Center, NRW.Global Business. Taros Chemicals

Oregon – booth GV11



Participating companies:

Araceli Biosciences, Business Oregon, Caravel Bio, Genentech, Oregon Health Sciences University, Oregon Life Sciences, Oregon State University

Portugal – booth GV21a



Participating companies:

Accelbio, AICEP, Genlbet Biopharmaceuticals - Recipharm, LXbio, Magmascience, Rodon Biologics, Universidade de Coimbra

Saxony – booth GV5



Participating companies:

AI-Driven Therapeutics, biosaxony/leap:up, Diamics, futuresax, Katana Labs, MDTB Cells, Saxocell, Saxony Trade & Invest

Slovenia – booth GV12



Participating companies:

Acies bio, Bio-ReCell, Brinox, Cleangrad, Herman & partnerji, Jafra, Labena, Lotric Metrology, Medis, Metronik, Naya Life Sciences, Priot, Zust-AI, Virella Science

South Korea – booth GV9



Participating companies:

AIT Studio, Anpoly, Cellnit, EZcaretech, Fustlab, Graphene Square Chemical, Ilias Biologics, Jetema, Korea Trade-Investment Promotion Agency, L-Base, Medipost, Moss Bio, Onesoftdigm, Preclina, Radahaim, Rokit Healthcare, Selexcine, ST Pharm

Spain – booth GV25c



Participating companies:

AseBio, BIOSPAIN

Taiwan – booth GV28



Participating companies:

Development Center for Biotechnology, Excelsior Biopharma, GlintMED Innovation, Kri-San Biotech, Mycenax Biotech, Onward Therapeutics, Protect Animal Health, Taiwan Bio Industry Organization

Delegation

UK – booth GV15



Participating companies:

ApconiX, BIA, BioAscent, Biocatalysts, BioPartner UK, British Embassy – Department for Business and Trade, British Embassy – Science and Technology Network, Centrix Pharma Solutions, CGT Catapult, CPI, Evestia Clinical, Firefinch, iGii, Ingenza, Lucideon, Medicines Discovery Catapult, Northern Light Microscopy, Pharmora, Rouken-Bio, Scancell, Sciento Technology, Scott Partnership Holdings, Seda PDS

Wallonia – booth GV22



Participating companies:

Approach Belgium, Ateliers Ferrari, Awex, Boostcode, Cenexi, Cer Groupe, Coris Bioconcept, ICTEAM institute, Icure Belgium, IDDI, Ipratech, Legiapark, MedReSyst, Oncoradiomics, Phoenix Biosciences, Qity, Sagitta Biotech, Salamander, Santero Therapeutics, Secoya Technologies, Seqalis, Syngulon, Telemedicine Technologies, The Clinical Pharmacology and Toxicology Research Unit, The Research Unit in Biology of Microorganisms, UCLouvain, Université libre de Bruxelles, White Raven

May 4, 18:00-18:45 International reception

Room San Francisco, level 3

Join us for a dedicated networking reception at the Global Village, where participants can connect with the international delegations in a relaxed and engaging setting. The event will feature welcome remarks by Michael Altorfer, CEO of the Swiss Biotech Association, and speeches from our long-standing Global Village partners: Switzerland Global Enterprise (S-GE) and Innosuisse.

The opening of the international reception will feature a performance on the alphorn, blending traditional sound with a modern interpretation.

May 5, 15:30-16:30 Marketplace reception

Room San Francisco, level 3

The Marketplace is the closing networking event of the Global Village, where international delegations will share drinks and snacks from their home countries—celebrating cultural diversity and global collaboration. Delegates will be invited to share their key achievements at Swiss Biotech Day and offer an outlook on future opportunities. The event will conclude with farewell speeches by Michael Altorfer, CEO, and Patrick Amstutz, President of the Board at the Swiss Biotech Association, including the announcement of this edition's country partnership of the year.

Bilateral roundtable discussions

Please join us for roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Day 1	San Francisco (stage)
14:00-14:30	Roundtable 1 – UK Engineering biology: Practical pathways for Swiss-UK cross-border collaboration
14:45-15:15	Roundtable 2 – Nordics Trusted Insights: A peer dialogue on biotech investment strategy
15:30-16:00	Roundtable 3 – Taiwan The Swiss-Taiwan biotech dialogue 2026: Driving cross-border partnerships in a shifting regulatory era
16:15-16:45	Roundtable 4 – Oregon Connecting engineering and biology ecosystems – from research to manufacturing
17:00-17:30	Roundtable 5 – Estonia-Lithuania Scaling successful collaboration models between Switzerland and the Baltics in life sciences

Day 2	San Francisco (stage)
12:00-12:30	Roundtable 6 – India Bridging innovation and scale: Building India-Switzerland biopharma value chains
12:45-13:15	Roundtable 7 – Spain Opportunities to strengthen the ties between Spanish startups and the Swiss ecosystem by leveraging Eureka instruments
13:30-14:00	Roundtable 8 – Netherlands Innovating women's health: Connecting Dutch and Swiss ecosystems
14:15-14:45	Roundtable 9 – France France - Switzerland: Transforming research into treatments faster
15:00-15:30	Roundtable 10 – China From catch-up to global partner: The implications of China's biotech rise for Europe

SWISS BIOTECH DAY

May 4–5, 2026
Congress Center Basel

The power of international collaboration Join our Global Village



- › Meet over 3,000 decision makers from about 50 countries
- › Connect with the global biotech community, CEOs and investors
- › Explore and initiate collaboration with Swiss biotech leaders
- › Drive cross-border investments
- › Build public/private partnerships
- › Enhance academic and translational cooperation
- › Share best practices and influence policy development
- › Promote talent exchange

The Global Village offers a continuous, year-round gateway for global biotech clusters to forge and deepen strategic, long-term partnerships within Switzerland's thriving biotech ecosystem.

If you are interested to participate in the Global Village find more info at swissbiotech.org/global-village and contact us at globalvillage@swissbiotech.org.

Presented by:



Swiss Biotech
Association

Supported by:



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Innosuisse – Swiss Innovation Agency

Global Village track

Presented by  **eureka**
innovation beyond borders

Supported by  Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Confederaziun Svizra

 **SWISS
BIOTECH**
Global Village

14:15-15:00 Plenary session

Room Osaka/Samarkand, level 3

Eureka: Non-dilutive funding for global innovation collaboration – opportunities for biotech

This plenary session will highlight Eureka, the world's largest public network for international R&D and innovation, spanning more than 45 countries. It will explore what makes non-dilutive funding programs effective for biotech and demonstrate how open, global collaboration models can broaden access to funding and accelerate innovation.

Moderation: **Andreas Gut**, Head of International Programs, Innosuisse

Panelists:

João Curado, CEO, Flomics Biotech

Bärbel Ulmer, Director Business Development, InSphero

Brit Helle, Director General, Eureka Secretariat

Laura Gunter, President, North Carolina Life Sciences Organization

Lorenzo Leoni, Founder and Managing Partner, Creadd Ventures

Presented by  **SWISS
BIOTECH**
Global Village

15:15-16:00 Panel

Room Osaka/Samarkand, level 3

Leveraging regulatory collaboration to strengthen public-private innovation partnerships

The panel will examine how the Access Consortium can move beyond regulatory alignment to enable coordinated evidence generation, faster system adoption, and scaled innovation. It will highlight public-private partnerships that reduce duplication across regulatory, HTA, and real-world evidence pathways, improving predictability for market access.

Participants will explore cross-border RWE collaboration, stronger investor confidence, and positioning Access countries as a globally competitive innovation bloc. The session will also introduce Access Innovation BioBridge as a non-regulatory platform to drive these efforts and launch near-term pilot.

Moderation: **Jaspreet K. Grewal**, Managing Partner, Access Innovation BioBridge

Panelists:

Jean-Paul Lemieux, Canadian Ambassador to Switzerland and Liechtenstein

Zara Asgharpour, Head of External Innovation, Lonza

Jörg Schläpfer, Chief of Staff and Head Sector External Relations, Swissmedic

Global Village track

Presented by **SWISS BIOTECH™**
Global Village

16:15-17:15 Pitch

Room Osaka/Samarkand, level 3

Global innovation showcase: Early-stage startups from the Global Village

Explore discovery and early preclinical biotech startups from around the world, developing innovative products and technologies to address global health challenges. Join us to discover the future of biotech, hear from visionary founders, and uncover exciting investment opportunities.

Moderation: **Maximilien Murone**, Liaison Basel Northwestern Switzerland, Swiss Biotech Association

Investor jury: **Michael Hübner**, Director Early Innovation Partnering, Johnson & Johnson | **Frederic Levy**, Chief Scientific Officer and Head of External & Internal Innovation, Debiopharm | **Georg Wiebecke**, Board Member, BioValley Basel | **Lorenzo Leoni**, Founder and Managing Partner, Creadd Ventures | **Diego Braguglia**, Managing Partner, VI Partners | **Jana Obajdin**, Analyst, BioGeneration Ventures

16:15 Introduction	16:45 Berking Theranostics
16:20 Phialogics	16:50 Virella Science
16:25 KinSea Lead Discovery	16:55 Summa Biotech
16:30 Cura Therapeutics	17:00 Jericho Science
16:35 Sagitta Biotech	17:05 iBody
16:40 Modulari-T Bioscience	17:10 Voting and closing remarks

Global Village track

Presented by **SWISS BIOTECH**
Global Village

12:15-13:00 Panel

Room Osaka/Samarkand, level 3

Strengthening Europe's biotech competitiveness through collaboration across the life science ecosystems

As Europe develops new policy instruments such as the upcoming EU Biotech Act, strengthening the competitiveness of its life science sector requires closer collaboration across the entire ecosystem – from established pharma and biotech hubs to emerging innovation regions. This panel will explore how different parts of Europe's life science landscape contribute to innovation capacity through talent, data, research and industrial capabilities. The discussion will focus on how stronger cross-regional and cross-sector collaboration can enhance Europe's global position in biotechnology.

Moderation: **Agne Vaitkeviciene**, Vice President, LithuaniaBIO

Panelists:

Sujoy Chowdhury, Senior Director Clinical Innovation & Operational Excellence (International Operations), Novo Nordisk

Ernst Nagel, Operations Director, Health Holland

Delphine Costa, CEO, The Life Science Cluster

Presented by **SWISS BIOTECH**
Global Village

13:15-14:15 Pitch

Room Osaka/Samarkand, level 3

Global innovation showcase: Late-stage startups from the Global Village

Explore late preclinical and clinical biotech startups from around the world, developing innovative products and technologies to address global health challenges. Join us to discover the future of biotech, hear from visionary founders, and uncover exciting investment opportunities.

Moderation: **Maximilien Murone**, Liaison Basel Northwestern Switzerland, Swiss Biotech Association

Investor jury: **Michael Hübner**, Director Early Innovation Partnering, Johnson & Johnson | **Kostas D. Kaloulis**, Venture Partner, ND Capital | **Jana Obajdin**, Analyst, BioGeneration Ventures | **Diego Braguglia**, Managing Partner, VI Partners

13:15 Introduction **13:45** TetraKit Technologies

13:20 PLL Therapeutics **13:50** Atrogi

13:25 CuraCell **13:50** Selexine

13:30 Ethris **13:55** Vactech

13:35 MDTB Cells **14:00** Apmonia Therapeutics

13:40 Isorea **14:05** Voting and closing remarks

Global Village track

Presented by  SWISS BIOTECH
Global Village

14:30-15:15 Panel

Room Osaka/Samarkand, level 3

Speed to clinic: Global perspectives on conducting clinical trials in Switzerland, Hong Kong, Australia and the MENA Region

Selecting the optimal location for early clinical trials can significantly influence the speed and success of biotech innovation. This panel will bring together key stakeholders from leading and emerging international ecosystems to discuss opportunities, regulatory pathways, and practical considerations for executing clinical trials across jurisdictions.

Moderation: **Simone Ferbitz-Scheurer**, Head of Clinical Trials Division, Swissmedic

Panelists:

Stella Sun, Principal Manager Life & Health Sciences, InvestHK

Eric Adam, COO, HAYA Therapeutics

Racha Fayad, Life Sciences Strategy Team, KPMG

Christel Gremion Viatte, Director Global Regulatory CTA, CSL

Shu Lam, Chief Business Development Officer, CMAX Clinical Research

Plenary session

10:00-12:00 Plenary session II

Room Montreal, level 2

Moderation: **Monika Jones**

10:00 Opening remarks

Michael Altorfer, CEO, Swiss Biotech Association

10:10 Keynote panel on Swiss biotech ecosystem

Host: **Patrick Amstutz**, President of the Swiss Biotech Association

Panelists:

Alex Mayweg, MD, Versant Ventures

Luca Santarelli, CEO, Windward Bio

Mark Dawson, Head, Roche Pharma Research and Early Development (pRED)

Otello Stampacchia, Founder Omega Ventures & Co-initiator of the European Life Science Coalition

10:55 Swiss Biotech Report

Frederik Schmachtenberg, Partner, Global Life Sciences Lead for Financial Accounting Advisory Services, EY

11:10 Swiss Biotech Success Stories Award

Jürg Zürcher, jury president

11:25 Investor panel: Cross-Atlantic perspectives on Swiss biotech

Host: **Seth Lewis**, Executive Vice President Corporate Finance, Molecular Partners

Panelists:

Andrew Hack, Bain Capital

Arjun Goyal, Vianti Capital

Naveed Siddiqi, Novo Ventures

Panels & pitches

Presented by  AESARA

09:00-09:45 Panel 13

Room Delhi, level 0

Betting on uncertainty: Navigating policy volatility in pharmaceutical investment and commercialization

Policy volatility and economic uncertainty are reshaping the pharmaceutical innovation landscape. From the Inflation Reduction Act in the USA, the EU pharma package, EU HTA legislation, and reshaped global reference pricing baskets following MFN actions from the US, investors and manufacturers alike are recalibrating their models for asset risk and reward. This panel brings together experts in finance, business development/licensing and commercialization to explore uncertainty – regulatory, political, and macroeconomic – impacts financing decisions for pipeline assets and go to market potential.

Moderation: **Jennifer Cain Birkmose**, Vice President Europe, Aesara

Panelists:

Sezai Taskin, CEO, ViferaXS

Michael Schroeter, Co-Head Sustainable Healthcare Equity, HSBC

Alina Levchuk, Head of Investor Relations, Nextech

Presented by



12:15-13:00 Pitch

Room Delhi, level 0

Showcasing the diversity of the Swiss industrial biotechnology

The industrial biotech pitching session will highlight the numerous industries in which biotech applications are used. It aims at presenting to the audience innovative companies active in foodtech, agritech and other fields, thereby highlighting the strength of this biotech segment.

Moderation: **Aditya Yellepeddi**, Head of industrial biotech chapter, Swiss Biotech Association

12:15 Introduction

12:20 SATW

12:40 Bionomous

12:25 Aleph Farms

12:45 NeoCarbons

12:30 The Cultured Hub

12:50 ADM International

12:35 Deasyl

12:55 Closing remarks

Panels & pitches

Presented by


13:00-13:45 Panel 19
Room Delhi, level 0

Scaling up fermentation: How to pass the burn-rate phase and achieve profitability at low risk

In the race for a profitable business model, every penny of the cost of goods sold (COGS) counts. While single-use technologies offer a seemingly low barrier to entry, their hidden operational costs can become a death trap for start-ups targeting food commodity markets. This session challenges the conventional wisdom of “throwaway”. We will explore how new approaches in stainless steel fermenter making can drastically reduce the initial CAPEX while ensuring minimum operational costs. Join us as we break down the Total Cost of Ownership (TCO) and find out why steel, powered by Blanc-Labo, is the leanest choice for your bottom line.

Moderation: **Eric Laborde**, CEO, BLANC-LABO

Panelists:

Klaus Kienle, Co-Founder and Chief Production Officer, Food Brewer

Pascal Torregrossa, Head Global Operations Active Beauty, Givaudan

Alexander Scheidel, Head of Bioprocessing Solutions, Steinecker - Kronos

Vivek Dogra, Co-Founder and General Partner, DDF Fund

Presented by


14:00-14:45 Panel 23
Room Delhi, level 0

Practical use of AI tools in fundraising, partnering & finance

AI tools for fundraising, business development and finance are now widely available, but while large pharma companies are starting to deploy them at scale, most smaller biotechs have yet to embed them into their core business processes due to constraints around budget, risk and governance. The panel will examine how this gap is reshaping deal-making dynamics, what it means for both sides of the table, and how smaller companies can respond in a legally robust and practically actionable way, including a pointer to a forthcoming webinar series that will continue the discussion with deeper, hands-on insights.

Moderation: **Philipp Gutzwiller**, Managing Partner, CFS Advisors

Panelists:

Luca Dal Molin, Partner, Homburger

Urs Breitenstein, Partner, Hoffmann & Partner

Avaleigh Milne, Global Head of Business Development Strategy & Practice, Pharma Partnering, Roche

Matti Kesti, CSO, Floatz.ai

Damian Kemper, Developer, Werchota.ai

Panels & pitches

Presented by  VERDEYA

15:00-15:45 Panel 27

Room Delhi, level 0

Medicinal and industrial use of the hemp plant: Innovations in Switzerland

Hemp is one of humanity's oldest cultivated crops and a cornerstone of sustainable innovation. Traditionally valued for durable fibres, hemp is now gaining renewed attention as a source of non-intoxicating cannabinoids such as cannabidiol (CBD). As scientific understanding and public acceptance grow, the industry faces new challenges in scaling from niche applications to global impact. This panel explores hemp's next development phase, highlighting innovation, regulatory evolution, and collaboration across medicine, wellness, food, and materials sectors.

Moderation: **Julia Hoeng**, VP Innovation & Product Development, Verdeya

Panelists:

Gavin George, Co-Founder and CEO, Purgene

Gordon Dawson, Director Product Development, Verdeya

Jürg Gertsch, Professor of Biochemistry and Pharmaceutical Biology, University of Bern

Hans Daetwyler, CEO, Swiss Plant Breeding Center

Tonio Schwehr, Applied Economist, EBP Schweiz

Presented by  Baker McKenzie.

16:00-16:45 Panel 31

Room Delhi, level 0

Building resilient, value-creating transactions in an unpredictable environment

As regulatory frameworks tighten and global headwinds disrupt some elements of traditional collaboration models, biotech dealmaking is facing new challenges. This discussion highlights the tools, terms, and strategic approaches that companies are using to build resilient, value-creating transactions in an unpredictable environment.

Moderation: **Julia Schieber**, Partner, Baker McKenzie

Panelists:

Oren Livne, Partner, Baker McKenzie

Antoine Khallouf, Managing Director, Rothschild & Co Global Advisory

Lev Kogon, Vice President and Head of Business Development, Stealth Mode Biotech

Panels & pitches

Presented by  PSI

09:00-09:45 Panel 14

Room Kairo, level 0

Agentic AI in clinical trials: Where are we now, and where are we going to be?

PSI CRO will host a dynamic session on agentic AI in clinical trials, exploring its capabilities and potential. Sponsors, AI experts, and PSI CRO will discuss its role in tackling protocol complexity, improving efficiency, and meeting evolving regulatory demands. We will review current applications of agentic AI across protocol design, startup, enrollment, and data analysis, alongside future advances such as adaptive trials and semi-autonomous monitoring. A moderated debate will explore the real value of agentic AI, barriers to adoption, and what we expect to come next.

Moderation: **Kirill Soldatov**, Head Process Improvement, PSI CRO

Panelists:

Florian Maurer, Head of Clinical Development, Basilea Pharmaceutica

Sezcan Ozturk, Head of Europe & Vice President, Luzsana Biotechnology

Daniel Morris, Solutions Engineer, Arango

Dmytro Baikov, Vice President of AI, DataArt

Presented by  BIOMEDVC

12:15-13:00 Panel 17

Room Kairo, level 0

Syndication in early-stage biotech: Chances and challenges

This panel explores early-stage biotech syndication between CVCs and seed investors. It covers roles, alignment, and evolving market dynamics, including selectivity and collaboration. Discussion highlights incentives, ticket sizes, and engagement, plus how strong syndicates are built and led. Panelists examine value inflection points, risk-sharing, and valuation trends. Differences between US and Europe are considered, alongside future funding roles. Challenges to syndicate financing rounds at early-stage will be discussed. Moderators will use prompts to deepen insight and reveal challenges, trade-offs, and practical lessons for founders.

Moderation: **Claudia Ulbrich**, Venture Partner, BiomedVC

Panelists:

Valentin Piech, Managing Partner, BiomedVC

Jan-Philipp Kruse, Senior Director, Lilly Ventures

Roger Franklin, Partner, Hadean Ventures

Naveed Siddiqi, Senior Partner, Novo Holdings

Mathias Frederiksen, Principal, Novartis Venture Fund

Panels & pitches

Presented by **CSL**

13:00-13:45 Panel 20

Room Kairo, level 0

Designing the next generation of partnerships

This panel will explore how partnership structures are evolving across the biotech lifecycle. Using recent European examples, including VarmX and Memo Therapeutics, the discussion will examine how deal design is adapted to asset maturity, available data and execution requirements. Spanning early platform collaborations through to late-stage development agreements, the panel brings together biotech, investor and industry perspectives, and will also reflect on Europe's role in supporting cross-border collaboration and company building.

Moderation: **Rémi Droller**, Managing Partner, Kurma Partners

Panelists:

Hervé Gisserot, Executive Vice President, CSL

Emmanuelle Lecomte-Brisset, Senior Vice President, CSL

Martijn Negen, Chief Operating Officer, VarmX

Lars Spenger, Chief Financial Officer, Memo Therapeutics

Presented by **Schellenberg
Wittmer**

14:00-14:45 Panel 24

Room Kairo, level 0

Life sciences ventures – exit strategies

When venture capital firms invest in private companies and publicly listed companies in sectors like pharmaceuticals, biotechnology, and medical devices, which questions need to be considered and addressed in advance to ensure successful exit transactions? Experts will discuss in a panel their experiences when establishing exit strategies.

Moderation: **Olivier Triebold**, Partner, Schellenberg Wittmer

Panelists:

Maximilian Stör, Head of Legal, Boehringer Ingelheim Venture Fund

Robert Stein, Partner, Gilde Healthcare

Pascal Hubli, Partner, Schellenberg Wittmer

Panels & pitches

Presented by  XDC
The Bioconjugation Center

15:00-15:45 Panel 28

Room Kairo, level 0

Beyond ADCs: The next wave of targeted bioconjugate therapeutics

Antibody drug conjugates (ADCs) transformed oncology, and bioconjugates are now expanding beyond ADCs. New modalities such as antibody oligonucleotide, peptide, degrader, and antibody fragment conjugates are enabling more precise targeting and new biology. This panel brings together pharma, biotech, venture, and CDMO leaders to discuss:

- Scientific breakthroughs driving new conjugate modalities
- Translating innovations into clinical development
- Manufacturing and quality challenges at scale
- Investment trends shaping the field
- The role of cross-industry collaboration in future innovation

Moderation: **Carl Deutsch**, CSO, NBE Therapeutics

Panelists:

Jimmy Li, CEO, WuXi XDC

Sherry Gu, CTO, WuXi Biologics

Frederic Levy, CSO, Debiopharm

Zhizhong Joel Yao, Partner, Sofinnova Partners

Presented by  Syneos
Health

16:00-16:45 Panel 32

Room Kairo, level 0

Beyond the data: Crafting the commercial story pharma partners believe in

In today's partnering environment, strong data alone no longer secures high value pharma deals. Successful assets are differentiated by the clarity and credibility of the commercial story behind them. This session brings together experienced dealmakers to explore how leading biotech teams translate clinical promise into narratives that resonate with potential pharma partners and investors. Through recent deal examples, the panel will examine how articulating the commercial story of the asset in a credible and realistic way, and how demonstrating execution understanding can accelerate trust and momentum, and shape deal success.

Moderation: **Marek Rombel**, Mng. Director Commercial Advisory Group, Syneos Health

Panelists:

Martijn Negen, Chief Operating Officer, VarmX

Artal Moreno-Fortuny, Exec. Director BD & Strategy, Alesta Therapeutics

Marc Hennebert, Managing Director Commercial Advisory Group, Syneos Health

Panels & pitches

Presented by  OBELYSQ

09:00-09:45 Panel 15

Room Shanghai 1+2, level 0

Implementation of a robust and pragmatic quality management system for biotechs

How to build your Quality Management System (QMS) without overcomplicating it, while meeting regulatory requirements?

This panel will explore how biotech companies can implement a QMS that is compliant, lean, fit-for-purpose, and sustainable – even with limited resources.

Bringing together experts who have navigated this journey from different perspectives, the discussion will focus on what truly matters: building a “right-sized” quality framework that meets regulatory expectations without unnecessary complexity.

Panelists will share real-world experiences on prioritizing and embedding quality into everyday operations.

Moderation: **Ludovic Moulin**, Managing Director, ObelysQ

Panelists:

Bettina Buddis, Head of Clinical Manufacturing, CDR-Life

Claudia Escher, Chief Operating Officer, Tolremo

Jan Krikava, Managing Director & Product Manager, Docuply

Arnaud Levain Chavanon, Managing Director, ObelysQ

Presented by  slas
Come Transform Research

12:15-13:00 Pitch

Room Shanghai 1+2, level 0

The SLAS startup pitch showcase

Selected startups will take the stage for a fast-paced, one-hour pitch session spotlighting breakthrough life sciences and lab automation technologies and commercial potential.

Modeled after SLAS Innovation AveNEW, our startup program evaluates compelling science, market opportunity and impact, and management team strength with an aim to connect innovators with industry users and investors. Prizes include a spot on SLAS Innovation AveNEW, plus awards from the city of Basel and Swiss Biotech Day.

Moderation: **Manuela Beil-Peter**, SLAS Europe Ambassador

Jury: **Olivier Frey**, Vice President Technology & Platforms, Insphero | **Samantha Paoletti**, Head Research and Business Development Life Science Technologies, CSEM | **Thomas Frech**, Lab Innovation Coach & Leader | **Kevin Keim**, Director Operations and Project Management, Walter Klybeck

12:20 Asemblis **12:40** Magnostics

12:30 AxCellerate **12:50** Prevision Medicine

Panels & pitches

Presented by   Swiss Biotech Association

13:00-13:45 Panel 21

Room Shanghai 1+2, level 0

From force to function: Empowering the next level of mechano-biology research

Cells and tissues are not only defined by their molecular composition but also by their mechanical properties, key drivers of function, disease progression, and therapeutic response. This panel brings together leading academic and industry experts to explore how advances in accessible, automated AFM technologies are opening mechanobiology to a much broader range of researchers.

Moderator and panelists can be found on our website

Presented by 

14:00-14:45 Panel 25

Room Shanghai 1+2, level 0

Operational maturity in CMC – accelerating development from strategy to execution

Most CMC (Chemistry, Manufacturing & Control) delays are predictable, yet they keep happening, because strategy and execution operate in silos.

This panel brings together leaders from biotech, pharma, and CDMOs to discuss how organizations build CMC readiness, align technical and business decisions, and close execution gaps that consume time and value. Perspectives across the development value chain, from early-stage decisions to commercial scale.

Moderation: **Sonja Merkas**, Founder and CEO, Livinovea

Panelists:

Christoph Becker, CEO, Inofea

Eduard Ayuso, CTO, Dinamiqs

Ivan Pogorelic, Head of CMC, Nxera Pharma

Jeffry Grunkemeyer, Associate Director Advanced Synthesis, Lonza

Panels & pitches

Presented by  solvias

15:00-15:45 Panel 29

Room Shanghai 1+2, level 0

Challenges and pitfalls in selecting and developing cell-based bioassays

Cell-based bioassays are a cornerstone of potency testing, safety assessment, and regulatory approval, as they provide data that more accurately reflects cellular behavior than assays targeting isolated components. However, their development is highly challenging due to biological variability, complex mechanisms of action, and evolving regulatory expectations, making CBBAs a high-stakes element of drug development. This panel will cover:

- Method selection for different modalities, with a focus on potency
- Key considerations and common pitfalls in assay development
- Examples of potency assays for mAbs, ADCs, and other biologics

Moderation: **Charlie Brault**, Digital Marketing Manager, Solvias

Panelists:

Daniel Galbraith, Chief Scientific Officer, Solvias

Thomas Millward, Director Bioanalytics, Novartis

Reginald Clayton, Director Field Development, Head of Biosafety, Solvias

Devadarssen Murdamoothoo, Director of Operations Cell-based Bioassay, Solvias

Presented by



16:00-16:45 Panel 33

Room Shanghai 1+2, level 0

Biosimilar development and commercialization: Challenges and opportunities

Biosimilars are reshaping healthcare; expanding access, challenging established markets, and creating new pathways for growth. But beyond science and strategy lies a bigger question: How do we turn opportunity into lasting impact? This panel brings together leaders from across the ecosystem to share perspectives on the evolving biosimilar landscape and what it takes to thrive within it. The discussion explores ambition and responsibility, highlighting the importance of collaboration, strategic execution, and sustainable value creation in a rapidly changing global environment.

Moderation: **Luc-Alain Savoy**, Global Head of Pharma, SGS

Panelists:

Haleh Hamedifar, Chairperson, CinnaGen

Benjamin Muller, CEO, Biofidus

Chris Lamb, CEO, Sealantium Medical

Eric Guenzi, CEO, UGA Biopharma

Panels & pitches

Presented by  CurieBio

09:00-09:45 Pitch

Room Shanghai 3+4, level 0

Reverse pitch: What top biotech VCs are looking for

In this unique session, leading biotech VCs pitch their investment models to founders. Learn how each firm thinks about scientific risk, team, and path to clinic – and what sets them apart. A must-attend for anyone looking to raise capital or understand today's biotech venture landscape.

Moderation: **Katharina Kreymbourg**, CurieBio

Jury: members can be found on our website

09:00 Introduction

09:09 CurieBio

09:27 Ysios

09:18 Wellington Partners

09:36 Closing remarks

Presented by  Swiss Biotech Association

12:15-13:00 Panel 18

Room Shanghai 3+4, level 0

Beyond equity: Navigating non-dilutive financing for growth

Equity is not the only path to fund innovation. This panel explores how biotech companies – from early stage to listed – can unlock capital through non-dilutive strategies. Our expert panelists from Switzerland and the United States will delve into early pharma collaborations / R&D partnerships, state-sponsored funding options and location packages, the power of royalty monetization, and value-creating outlicensing or spin-off structures. The session will highlight practical deal structures, key Swiss law and tax aspects, and real-world lessons on how to finance growth while preserving equity and strategic flexibility.

Moderation: **Daniel Häusermann**, Partner, Homburger

Panelists:

Fabian Meier, Partner, EY

Hannah England, Partner, Ropes & Gray

Vincent Reardon, Partner, Vischer

Maurus Winzap, Partner, Walder Wyss

Panels & pitches

Presented by  WuXi AppTec

13:00-13:45 Panel 22

Room Shanghai 3+4, level 0

RNA therapeutics: From breakthrough science to scalable reality

RNA therapeutics are rapidly reshaping drug discovery, expanding opportunities far beyond mRNA vaccines. This panel brings together industry leaders and investors to explore how scientific innovation is translated into clinical and commercial success. From advances in RNA chemistry and delivery to manufacturing scale-up and funding strategies, panelists will share insights on key challenges and opportunities shaping the next wave of RNA-based medicines.

Moderation: **Dave Madge**, Vice President Discovery Services, WuXi AppTec

Panelists:

Keith Philipps, Vice President Head of Grünenthal Genetic Medicine, Grünenthal

Hans Kistemaker, Principal CMC Consultant, Kistemaker Pharma Consultancy

Samir Ounzain, CEO, Haya Therapeutics

Sara Trifari, CSO, T-ONE Therapeutics

Tiziana Rossetti, Principal, Sofinnova Partners

Anne Grahl, Investment Manager, Pureos Bioventures

Presented by  MOLECULAR partners

14:00-14:45 Panel 26

Room Shanghai 3+4, level 0

How Switzerland can lead in the radiopharmaceutical industry and how to enable its full potential

For over a decade, pharma and biotech companies as well as academic centers and researchers in Switzerland have been at the forefront of nuclear medicine. As the field of radiopharmaceuticals continues to grow, we discuss how Switzerland can continue to lead and how to enable its full potential in this next era of innovation for cancer patients.

Moderation: **Philippe Girard**, Deputy Executive Director, Swissmedic

Panelists:

Philippe Legenne, CMO, Molecular Partners

Andrew Cavey, CEO, ITM Radiopharma

Leila Jaafar, CEO, Nuclidium

John Prior, Professor and Head of Nuclear Medicine and Molecular Imaging, CHUV

Panels & pitches

Presented by **SIEMENS**

15:00-15:45 Panel 30

Room Shanghai 3+4, level 0

Accelerating biotech: How AI, automation and virtual simulation are transforming lab design and operations

Our expert panel, featuring leaders from industry, ecosystem, and tech, who are going to delve into the transformative power of AI, automation, and virtual simulation in biotech. They will explore how these technologies are reshaping lab design and operations, discussing practical applications, benefits, challenges, and exciting future trends.

Moderation: **Jens Feddern**, Head of Life Sciences CH, Siemens Smart Infrastructure

Panelists:

Tom Kissling, pRED Lab Automation Partner, Roche

Deborah Lancaster, Partner Life Science Strategy, KPMG

Tim Walsh, Global Solutions Director, Siemens Smart Infrastructure

Presented by  **VirdisGroup**
INTERNATIONAL VENTURE CAPITAL GROUP LTD

16:00-16:45 Panel 34

Room Shanghai 3+4, level 0

Talent, tenacity, and transformation: Redefining success in biotech startups

This panel dives into what it really takes to succeed as a biotech entrepreneur, from the mindset, tenacity, and skills you need to building teams that can deliver. Founders and experts share real-world lessons on tackling scientific, regulatory, and business challenges, spotting talent, and learning and adapting fast to thrive in the biotech world.

Moderation: **Natasha Konstantinova**, Head of Talent and Academy, Swiss Biotech Association

Panelists:

Laurent Massuyeau, Founder, iQone Healthcare Switzerland

Nicholas Drager, Founder and Director, Cederberg

Nathalie Rowell, CEO, Virdis Group

Guido Zaman, Founder, Oncolines

Panels & pitches

Presented by

**09:00-09:45 Panel 16****Room Singapore, level 2**

Clinical trials in Europe done right, operational excellence and smart use of scientific advice

This session provides practical insights into planning and executing clinical trials in Europe, focusing on operational excellence and strategic use of Scientific Advice. It covers efficient navigation of CTIS, including country selection, timelines, and ways to accelerate approvals while ensuring compliance. In addition, it highlights how Scientific Advice can de-risk development, align with regulators, and optimize pathways. Participants will gain actionable insights to manage complexity, avoid pitfalls, and enable timely, successful clinical development.

Moderation: **Ursula Türcke**, Senior Director Clinical Operations, FGK

Panelists:

Stephanie Krumholz, Founder and CEO, therainnova

Martin Krauss, Founder and Managing Director, FGK

Find details about the panel discussions here... →







... and about the pitching sessions here →



Emerging biotech companies

Presented by **PUREOS**
BIOVENTURES

Room Singapore, level 2

Time	Company	
12:45	Cellvie	
13:00	Akylox Therapeutics	
13:15	Peptone	
13:30	Red Ridge Bio	
13:45	Arphamid Therapeutics	
14:00	GliaPharm	
14:15	Shape Biopharma	
14:30	Break	
14:45	AtheBio spin-off	
15:00	ClexBio	
15:15	Nanolynx Biologics	
15:30	Biodelphis Therapeutics	
15:45	Break	
16:00	Amporin Pharmaceuticals	
16:15	Limula	

Moderation: **Veronica Gambillara Fonck**, Partner, Pureos Bioventures
Butrint Aliu, Associate, Pureos Bioventures

Clinical stage companies

Presented by



Time	Company	Room Montreal, level 2
12:30	Celonic	
12:45	Molecular Partners	
13:00	FoRx Therapeutics	
13:15	Memo Therapeutics	
13:30	Nouscom	
13:45	AlphaMol Science	
14:00	3T Biosciences	
14:15	Diatheva	
14:30	Curatis	
14:45	Step Pharma	

Moderation: **Georg Blaser**, VP of Biologics Development Center, Celonic Group

Presented by



15:15-16:15 Pitch

Room Montreal, level 2

Reverse investor pitch









In this pitch, investors demonstrate why they stand out as strong and trusted partners for ambitious founders and high-potential businesses. They highlight the distinctiveness of their investment strategy, their hands-on approach, and the unique value they create beyond capital through expertise, networks, and long-term partnership.

Moderation: **Lorenzo Leoni**, Managing Partner, Creadd Ventures

15:15	Apollo	15:45	Creadd
15:21	BaseLaunch	15:51	Forbion
15:27	BioGeneration Ventures	15:57	Nextech
15:33	BiomedVC	16:03	VI Partner
15:39	deepbright ventures	16:09	XGEN

Commercial stage companies

Presented by **LONZA**

Time	Company	Room Sydney, level 2
12:30	Lonza	LONZA
12:45	Samsung Biologics	SAMSUNG BIOLOGICS
13:00	HDI Global	HDI
13:15	Concept Life Science	 CONCEPT LIFE SCIENCES
13:30	Cytiva Europe	 cytiva
13:45	Acumetis	Acumetis
14:00	Genomics	GENOMICS
14:15	BioAgilytix	BioAgilytix 
14:30	Break	
14:45	HAS	 HAS Group
15:00	MSD	 MSD
15:15	Johnson & Johnson	Johnson&Johnson
15:30	Ropes & Gray	ROPES & GRAY
15:45	Carterra	 carterra
16:00	LIDE Biotech	 LIDE
16:15	Davis Polk & Wardwell	Davis Polk
16:30	TwinEdge Biosciences	 twinedge BIOSCIENCE

Moderation: **Philipp Markolin**, Senior Manager, Integrated Biologics, Lonza

Moderated networking tables

Presented by  **DINAMIQS**
a Seqirus company

12:10-12:40 Networking table 5

Room Rio, level 2

From science to commercialization: Can Switzerland lead the advanced therapies revolution?

Advanced Therapies (AT) have delivered remarkable clinical successes in recent years, transforming the treatment landscape for previously untreatable diseases. However, their broader impact remains constrained by significant challenges including manufacturability, scalability, consistency, and cost. This roundtable will explore the AT revolution, with a focus on cell and gene therapies and the critical role of viral vector CDMOs in enabling their commercialization. The discussion will bring together expert perspectives on how Switzerland can leverage its strengths to accelerate the translation of innovation into commercially viable therapies.

Moderation: **Luk H. Vandenberghe**, Associate Professor Harvard Medical School, Director Grousbeck Gene Therapy Center

Presented by  **CLINILABS**
a CRO with you

12:50-13:20 Networking table 6

Room Rio, level 2

How AI is accelerating drug development from discovery to clinical

Artificial intelligence is accelerating clinical development by enabling smarter trial design, faster patient identification, and real-time data insights. Across discovery and preclinical stages, AI reduces early risk by improving target selection and translational confidence. In the clinic, AI supports precision recruitment, adaptive protocols, and proactive trial monitoring – helping sponsors shorten timelines, reduce costs, and increase probability of success from first-in-human through late-stage development.

Presented by  **DataArt**

14:50-15:20 Networking table 7

Room Rio, level 2


Building the intelligent trial: What it takes to scale AI across sponsors, CROs, and sites

Scaling AI across clinical trials offers substantial benefits but brings unique challenges. Join an interactive discussion led by Dmytro Baikov, VP of AI at DataArt, to explore how to incorporate and scale AI across sponsors, CROs, and sites. Assess your organization's AI maturity, share key obstacles, and identify real barriers to progress. Together, we'll develop practical, cross-industry takeaways for building AI that scales.

Moderation: **Dmytro Baikov**, Vice President of AI, DataArt
Sue Tripathi, Chief Data Officer, DataArt

Floor plan

Level 1




Level 0



Floor plan

Level 3



Level 2



Explanation of symbols on following page

Floor plan

- Conference rooms
 - Exhibitor booth
 - Catering
 - Barista station
 - Media table
 - Partnering helpdesk
- Partnering tables:

 - 👤 pink - 1001-1030
 - 👤 blue - 2001-2050
 - 👤 purple - 3001-3050
 - 📄 Poster exhibition
 - 🛋️ Lounge area
- 📷 Photo point
 - 🚪 Stairs
 - 🚶 Escalator
 - ♿ Restrooms






















Overview of conference rooms		
Name	Level	Program
Delhi	0	Panels & pitches
Kairo	0	Panels & pitches
Shanghai 1+2	0	Panels & pitches
Shanghai 3+4	0	Panels & pitches
Montreal	2	Plenary sessions Clinical stage company presentations
Singapore	2	Emerging company presentations Pitches
Sydney	2	Commercial stage company presentations
Rio	2	Moderated networking tables
Mexico	2	Roundtable
San Francisco	3	Global Village roundtables
Osaka/Samarkand	3	Global Village panels & pitches

Scan the QR code to access the interactive floor plan, where you can easily locate session rooms, partnering areas, and exhibitor booths. To find an exhibitor's exact location and company information, select a booth number or exhibitor name. You can also explore the partnering, panel, and pitching areas for more details.























Not sure where to go? Just ask our friendly staff in the green 'Ask Me!' T-shirts.






















Exhibitors | level 2

Booth	Exhibitor	
#1	Swiss Biotech Association	
#2	...and their friends	
#3	KBI Biopharma	
#4	Biopôle	
#5	Carbogen	
#6	CSL Behring	
#7	Fortrea	
#8	Crown Biosciences	
#8a	ICOSAGEN	
#9	Siegfried Dinamiqs	
#10	PolyPeptide Group	
#11	Comac Medical	
#12	Accelsiors	
#13	Experimental Pharmacology & Oncology Berlin-Buch	
#14	Syspro Automation	
#15	Pharmaron	
#16	Lonza	
#17	Citibank	
#18	Swissmedic	
#19	Veristat	
#20	Macrogen Europe	





















Exhibitors | level 2

Booth	Exhibitor	
#21	Almac Group	
#22	B. Braun Medical	
#23	Quality Assistance	
#24	CROss Research	
#25	Veranova	
#26	Superlab Suisse	
#27	SGS Analytics	
#28	YUMAB	
#29	Leukocare	
#30	Celonic	
#31	Ardena	
#32	WuXi AppTec	
#33	Hamilton Bonaduz	
#34	Citeline	
#35	Philip Morris International	
#36	ICE Bioscience	
#37	FGK Clinical Research	
#38	LubioScience	
#39	Nikon	
#40	Genesupport	 






















Exhibitors | level 2

Booth	Exhibitor	
#41	Labcorp	
#41 a	AlphaSense	
#42	Allucent	
#43	Tigerméd	
#44	WuXi XDC	
#45	Clinigen Clinical Supplies	
#46	Microsynth	
#47	Stemcell	
#48	Artidis	
#49	Cytiva	
#50	Parexel	
#51	Obelysq	
#52	Worldwide Clinical Trials	
#53	MLM Medical Labs	
#54	nNano	
#55	CSEM	
#56	Hoffmann & Partner	
#57	Cetacea Clinical	
#58	Quotient Sciences	
#59	BioAgilytix	
#60	Pharmadule Morimatsu	

Exhibitors | level 0

Booth	Exhibitor	
#61	PSI CRO	
#62	BellenChem	
#63	Unchained Labs	
#64	Dottikon	
#65	Eurofins BioPharma Product Testing	
#66	White Raven	
#67	ZentriForce	
#68	Schedio	
#69	Concept Life Sciences	
#70	Neuchâtel/Fribourg	
#71	Jacobs	
#72	Onyx Scientific	
#73	Proteintech Europe	
#74	Gempharmatech	
#75	Luminance Health	
#76	Asymchem Laboratories	
#77	Pharmarketing	
#78	Clean Cells	
#79	Validated Cloud	
#80	DHL Express	






Exhibitors | level 0

Booth	Exhibitor
#81	CRYOPDP Global Services 
#82	Neurosyst 
#83	Toxstrategies  BlueRidge 
#84	Revvity 
#85	Real Chemistry 
#86	CinnaGen 
#87	Kactus 
#88	EastMabBio 
#89	Solid State Pharma 
#90	Cytion 
#91	Canfield Scientific 
#92	Sartorius Stedim 
#93	Brand Institute 
#94	Midas Pharma 
#95	Hettich 
#96	Samsung Biologics 
#97	Vector Builder 
#98	Juvion Health Sciences 
#99	Genevant 
#100	Alma Technik 

Exhibitors | level 0

Booth	Exhibitor	
#101	Solvias	
#102	Eppendorf	
#103	Vetter Pharma	
#104	Walter	
#105	Carterra	
#106	Aptar Pharma	
#107	Farmhispania Group	
#108	Getinge Deutschland	
#109	Cube Biotech	
#110	BioPharmaSpec	
#111	Astrum CRO	
#112	Bioconcept	
#113	Arex Advisor	
#114	Yaohaibio	
#115	Productlife-Group	
#116	Diatheva	
#117	BAG Healthcare	
#118	Thermo Fisher Scientific	
#119	Bachem	
#120	ten23 Health	

Exhibitors | level 0

Booth	Exhibitor	
#121	Space Peptides	
#122	Euromed Pharma	
#123	Kaye – Subsidiary of Amphenol	
#124	Minaris	
#125	Zeta	
#126	Richter Biologics	
#127	Genevoyager	

Find further information about the exhibitors here →



Mentoring booths | level 3

The mentoring booths offer personalized guidance by specializing in topics relevant to biotech CEOs across the entire value chain.

Booth	Exhibitor
#MB1	<p>Going global: International business & export Switzerland Global Enterprise</p> 
#MB2	<p>Non-dilutive including European funding Innosuisse & Euresearch</p>  
#MB3	<p>Access international R&D funding Eureka</p> 
#MB4	<p>Successful innovation: Entrepreneurship, collaborations, teambuilding, IP strategy Viopas Venture Consulting, Strategic Transactions Advisory, Strategic Coulter Partners, JFIPS</p> 
#MB5	<p>Swiss Biotech Association legal/tax/accounting: (Non-dilutive) financing Q&A Swiss Biotech Association, EY, Vischer, Homburger, WalderWyss</p> 
#MB6	<p>From science to deal: Optimizing enterprise value CRA International</p> 
#MB7	<p>Ready to turn compliance into your competitive advantage? Heidelberg & Partners</p> 
#MB8	<p>From local biotech innovators to global champions: Financing, M&A & IPOs Stifel</p> 
#MB9	<p>Accelerating healthcare through microgravity Exobiosphere</p>  

Swiss cluster booths | level 3

The Swiss cluster booths exhibit the innovation power of Switzerland. Selected clusters offer insight into their activities and are interested in exploring collaboration opportunities.

Booth	Exhibitor	
#SC1	Università della Svizzera Italiana USI Startup Centre	
#SC2	Valais Cluster BioArk, HES-SO Valais-Wallis	
#SC3	Bern Life Science Hub BernExpo, Sitem Insel	
#SC4	Microphysiological Systems Innovation Hub Alveolix, inSphero, Mimetas	
#SC5	Biotechnet Switzerland Biotechnet, ZHAW, FHNW, University of Zurich, University of Bern, FR Institute of Chemical Technology, Swiss TPH	
#SC6	Life Science Zurich Business Network (LSZBN) LSZBN, Bio-Technopark Schlieren-Zürich	
#SC7	Image Acquisition & AI-Driven Analysis at ETH & EPFL ScopeM, EPFL	
#SC8	Lausanne Research UNIL-CHUV, Ludwig Institute	
#SC9	Swiss Clinical and Translational Research Cluster Swiss Medical Network, Genolier	
#SC10	HE-Arc Microcity Microcity, HE-Arc	
#SC11	PULSE – Modular Life Science Center PULSE by Epic	

Poster presentation

No.	Company	Level
#01	Abbmira Therapeutics	1
#02	Adoram Therapeutics	1
#03	AevX Therapeutics	1
#04	ALP AI	1
#05	AlveoliX	1
#06	Amporin Pharmaceuticals	1
#07	Antion Biosciences	1
#08	Asemblis	1
#09	Athebio	1
#10	AxCellerate	1
#11	BigOmics	1
#12	Biodelphis	1
#13	Bioscibex	1
#14	BioVersys	1
#15	Caldre	1
#16	ChAlron	1
#17	Crosswalk Therapeutics	1
#18	Damian Pharma	1
#19	DiNAMIQS	1
#20	Elionova	1
#21	Enantios	1
#22	EsoCap	1
#23	Eviive	1
#24	FluoSphera	1
#25	FoRx Therapeutics	1
#26	Fy Cappa Biologics	1
#27	Gibela Therapeutics	1
#28	GlycoEra	1
#29	Hemastatx	1
#30	IBEX Therapeutics	1
#31	Immunophotonics	1

No.	Company	Level
#33	InSphero	1
#34	InVirtuo Labs	1
#35	Jantar	1
#36	Juvion Health Sciences	1
#37	Limula	1
#38	Linkster Therapeutics	1
#39	Memo Therapeutics	1
#40	Metys Pharmaceuticals	1
#41	Nanolynx Biologics	1
#42	NanThermix	1
#43	NewBiologix	1
#44	NewBiologix	1
#45	Nouscom	1
#46	Nuantic	1
#47	OM Pharma	1
#48	ONtrack	1
#49	Onward Therapeutics	1
#50	OptoLumina	1
#51	Parithera	1
#52	PDC Therapeutics	1
#53	Perseo Pharma	1
#54	Pilatus	1
#55	Prevision Medicine	1
#56	Procavea Biotech	1
#57	Pure-DEL	1
#58	QuantBio	1
#59	Regenera	1
#60	REM Analytics	1
#61	Selmod	1
#62	Shape Biopharma	1
#63	Shrare	1

Poster presentation

No.	Company	Level
#64	Somagenetix	1
#65	SpiroChem	1
#66	Stämm	1
#67	SunRegen Healthcare	1
#68	Sydra Biotech	1
#69	Synameta Therapeutics	1
#70	Synendos Therapeutics	1
#71	Tandem Therapeutics	1
#72	TissueLabs	1

No.	Company	Level
#73	TransHeps	1
#74	Trillium	1
#75	Twinedge Biosciences	1
#76	Visienco	1
#78	Xemperia	1
#79	Ymmunbio	1
#80	Beyond Genomix	1
#81	NagiBio	1
#82	Swiss Rockets	1

Swiss Biotech Success Stories

No.	Laureate	Level
S 01	Swiss Biotech Success Stories Awards, categories & jury	3
S 02	Actelion Patrick Aebischer	3
S 03	Werner Arber Bachem	3
S 04	Basilea Biogen	3
S 05	Debiopharm ESBATech	3
S 06	FSRMM Genedata	3
S 07	Glycart Helsinn	3
S 08	Humabs BioMed/Vir Etienne Jornod	3
S 09	Lonza Henri B. Meier	3
S 10	Novimmune Okairos	3
S 11	Selexis Sophia Genetics	3
S 12	Hans-Peter Strebel venture, Venturelab, Venture Kick	3
S 13	Vifor Pascale Vonmont	3

Where to find the posters

- Posters of Swiss biotech R&D companies are being shown on level 1
- Posters of Swiss Biotech Success Stories Award winners are being shown on level 3

There will be dedicated poster sessions on Monday, May 4, 16:15 - 17:00, and on Tuesday, May 5, 14:45 - 15:30

Participating companies

(as of 21 April 2026)

Member of the Swiss Biotech Association

Company	Country
[i]to] Business Intelligence	DE
10x Genomics	NL
20/20 OptimEyes Technologies	CA
201 Therapeutics	CH
360biolabs	AU
3BIOTECH	FR
3DBioFibR	CA
3i Group Plc	CH
3T Biosciences Europe GmbH	CH
4basebio	UK
4Bases SA	CH
4G Clinical, B.V	NL
5 Prime Sciences	CA
7AlpsBio GmbH	CH
a-connect	CH
A/S Metroserf	EE
A&O Pharma	DE
AB2 Bio Ltd	CH
Abbelight	FR
Abbmira Therapeutics AG	CH
abc bioply ag	CH
abcDNA GmbH	CH
ABclonal Biotechnology	CN/DE
Abcured	GR
Able Tx	IL
Ablevia biotech	AT
ABS Biotechnologies	AT
Abselion	UK
Abzena	UK
AcademicLabs	BE
Acapo Onsagers AS	NO
ACBio Marketing Consulting Sagl	CH
ACCELERERA Srl	IT
acella advisors	CH
Accelsiors AG	CH
Access Innovation BioBridge	CA
Accord Medica	US

Company	Country
Acies bio d.o.o	SI
ACM Biosciences AG	CH
acmaios	DE
AD-MSAT biopharm	FR
Adamastor Bioservices Srl	IT
ADARE PHARMACEUTICALS SRL	IT
Adimab	US
Adiposs SA	CH
ADM International Sarl	CH
ADMEDDICON - DMPK Consulting	DE
admedicum & KG	DE
Adolf Kühner AG	CH
Adoram Therapeutics SA	CH
Adryan	CH
Adularia AG	CH
Advanced Clinical Switzerland GmbH	CH
Advanthink	FR
AdveNeuro SA	CH
Advestra	CH
Adwiss service sarl	CH
aevX Bio SA	CH
Africa Collective	CH
Aganitha AI	IN
AGC Biologics	DK
Agility Life Sciences	UK
Agro-Bio	FR
AI Invest Lab	LV
AI-Driven Therapeutics	DE
AICEP Portugal Trade & Invest	CH/PT
aimed analytics GmbH	DE
AIT STUDIO	KR
akampion	DE
Akceso Advisors AG	CH
Albor Biotech SL	ES
Alentis Therapeutics AG	CH
Aleph Farms AG	CH
Alfa Laval Mid Europe	CH

Participating companies

Company	Country
Alira Health	DE/ES/IT
Alira Health AG	CH
Allthea Genomics SA	CH
Allegria Therapeutics AG	CH
Alltim	CH
Allucent	UK/NL
Almac Group	UK
Almasan	CH
Almatechnik TDF	CH
Almelo Private Limited	IN
ALP Bio AG	CH
Alpha Lyncis SA	CH
Alphalyse A/S	DK
AlphaMol Science AG	CH
AlphaSense	UK
Alpinity Bio GmbH	CH
Altasciences	CA
Alter Ego biotech	FR
Alterbiotix	CH
Altorfer Engineering GmbH	CH
AlveoliX AG	CH
Ambiotis	FR
AmphiliX AG	CH
Ampleia	FR
Amporin Pharmaceuticals AG	CH
AnaPath	ES
AnaPath	CH
Anapharm Bioanalytics	ES
Anaveon AG	CH
AND Biotech AG	CH
Andreas Hettich	DE
ANPOLY	KR
anteris helvetia AG - Kymanox Europe	CH
Antibody Analytics trading as RoukenBio	UK
Antibody Design	UK
ANTINEO SAS	FR
Antion Biosciences SA	CH
ApconiX	UK

Company	Country
Apellis	CH
Apeloa Europe	DE
Aphaia Pharma AG	CH
APICES	ES
ApiniLabs	CH
APMONIA THERAPEUTICS	FR
APNC Sweden	SE
Apollo Health Ventures	LU
Approach Belgium	BE
APR Applied Pharma Research SA	CH
Aptar Pharma	FR
ArabMed CRO	SA
Aracell Biosciences	US
Aragen Life Sciences	IN
Araris Biotech AG	CH
ArcanaBio ApS	DK
Arcera Life Sciences	CH
Arcinova, A Quotient Sciences Company	UK
Arcondis	CH
arcoris bio AG	CH
Arctoris	UK
Ardena	BE
Arex Advisor	CH
Argentum Consultants	IL
ARKGEN BioScions	KR
Arkivum	UK
Arphamid Therapeutics SAS	FR
Arriello Ireland Limited	IE
ARTCLINE	DE
Artman Technologies	SK
Aryastha Life Sciences	IN
Asahi Kasei Pharma Corporation	JP
Ascelis Peptides	IN
Ascend Advance Therapies	US
Asceneuron SA	CH
Asemblis GmbH	CH
ASGENTO	DE
Asimov	UK

Participating companies

Company	Country
Aspeya Switzerland SA	CH
Astellas	UK
AstraZeneca	CH
Astrum	FR/PT/DE
Asymchem	US
AT-31 BIO Inc.	KR
ATANIS Biotech AG	CH
ATG Therapeutics	ES
Athebio AG	CH
Atlantic BioCorp	CA
Atopia Therapeutics	CH
Atrogi AB	SE
Aukera Therapeutics GmbH	CH
Aurlide Oy	FI
Aurum Biosciences	UK
Austrade	AU/DE
Australian Embassy Bern	CH
Austrian Business Agency	AT
AUVERGNE- RHONE-ALPES ENTREPRISES	FR
Auxenion Research AG	CH
Avance Basel GmbH	CH
AVEctivate GmbH	CH
Avenza Consulting Sàrl	CH
AVS Bio Netherlands B.V	NL
avs engineering	DE
AWEX - Wallonia Export & Investment Agency	BE
AxCelerate Sagl	CH
axcura AG	CH
AXFENBIO	FR
Explora	DE
Axxam SpA	IT
Azafaros Switzerland AG	CH
Azur Health Science	FR
AzureCell SA	CH
B2B Swiss Medien	CH
Baccinex SA	CH
Bachem AG	CH

Company	Country
BACHMANN FORMING	CH
BackingHerVenture e.V	DE
Baden-Württemberg International	DE
Bain Capital Life Sciences	US
Baio Labs	CH
Baker & McKenzie LLP	UK
Baker McKenzie Switzerland AG	CH
Balgrist Campus	CH
Baliopharm AG	CH
Bambooster	CH
bamconn	DE
Banook	FR
BAP Pharma	DE
Bär & Karrer	CH
Barré	BE
Barrington James	UK
Basel Area Business & Innovation	CH
Basel Biotech Consulting GmbH	CH
Basel Tourismus	CH
BaseLaunch	CH
Basilea Pharmaceutica AG	CH
Basler Zeitung	CH
Batea Oncology	ES
Bavarian Nordic Berna GmbH	CH
Baxiva	CH
Bayern International	DE
BD as a Service	CH
Becton Dickinson AG	CH
BeCytes Biotechnologies	ES
Belgian Embassy / Wallonie-Bruxelles International	BE
Benevolent AI	UK
Bentleys	AU
BeOne Medicines I GmbH	CH
Berlin Partner für Wirtschaft und Technologie	DE
Bernhard Fischer Consulting and SICC	CH
BERNINA BioInvest AG	CH
bespark bio	AT

Participating companies

Company	Country
BespokExe sarl	CH
Betta Scientific AG	CH
BFlow	ES
BIA	UK
Bicoll	DE
BIMOVIS	DE
Bio-Rad Laboratories AG	CH
Bio-ReCell d.o.o	SI
Bio-Research.AI	KR
Bio-Techne AG	CH
Bio-Technopark Schlieren-Zürich	CH
BIO.NRW	DE
BioAgilytix	DE
BioAlps Association	CH
Bioark SA	CH
BioAro	CA
BioAudix	CH
BioBox	CA
BioCina	AU
BioConcept AG	CH
Biocytogen	CN/US
Biodelphis Therapeutics SA	CH
BioDuro	US
Bioengineering AG	CH
Biofactory Competence Center	CH
BioFi	CH
Biofidus	DE
biogem sarl	IT
Biogen International GmbH	CH
BioGeneration Ventures	NL
BioGenes	DE
Biognosys	FR
BioIVT	CH/DE/IT
Biokanzlei	AT
BioKryo	DE
Biolacuna Limited	UK
BioLingus IP II GmbH	CH

Company	Country
BioLink Intelligence	DE
BioLizard SA	CH
BioM Biotech Cluster Development	DE
BiomedVC AG	CH
bioMérieux (SUISSE)	CH
Biomia	DK
BiomimX	IT
biomindz	DE
Biomine Health	ZA
BIONCaRT	DE
Bioneer A/S	DK
Bionomus SA	CH
Bionrec	DE
BioPark Regensburg	DE
Biopath Consulting	DE
BioPharmaSpec	DE
Biopôle SA	CH
BIOPRO Baden-Württemberg	DE
Biorce	ES
BioReliance® Services	UK
BIOREP S.r.l	IT
bioRN Life Science Cluster	DE
Biosan SIA	LV
biosaxony e.V. / leap:up	DE
Bioscibex SA	CH
BIOSEB	FR
Biosimulytics Limited	IE
BioSpace	US
Biosynth	CH
Biotecha	LT
Biotechnet Switzerland	CH
Biotika a.s	SK
Biotrial	FR
Bious Labs	LT
BioValley France	FR
BioVersys AG	CH
Biovia	BE

Participating companies

Company	Country
BioWorld Today	UK
BioX Technologies	SK
BioXpress Therapeutics SA	CH
BirchBioMed	CA
Black Fountain Capital	CH
Black Label Sp. z o.o	PL
BLACKTHORN AI	UK
BLINK	DE
Blue Ocean Technologies	CA
Bluepharma	PT
Blueprint Medicines (Switzerland) GmbH	CH
BMD Life Sciences	DE
Boehringer Ingelheim International	DE
Bo azıci University	TR
Böhler Life Science Advice	CH
Bonetti & Partner GmbH	CH
BOOT HC	IT
Boston Institute of Biotechnology	CN
Boydell Global Executive Search	CH
BRAINBiocatalysts	UK
BRAND INSTITUTE	US
BREAKLINE RESOLUTION	CH
Brenus Pharma	FR
Brinox d.o.o	SI
Brinox Innovations	CH
Bristol-Myers Squibb	CH
British Embassy in Switzerland	CH
Business & Economic Development Zurich	CH
Business Finland	DE/FI
Business France Switzerland	CH
Business Oregon	DE/US
Business Parc	CH
BusinessPA - Pennsylvania Investment Office	CH/DE
Byondis B.V	NL
C2 Health Consulting	CH
CADFEM (Suisse)	CH
CALDRE AG	CH
Calliditas Therapeutics Suisse SA	CH

Company	Country
Cambrex Profarmaco Milano SRL	IT
Camera di Commercio Italiana per la Svizzera	CH
Campus Biotech Geneva Foundation	CH
Campus Technologies Freiburg	DE
Cancer Research and Biotechnology AG	CH
Canfield Scientific	NL/US
Canton Biologics	CN
CanVirex AG	CH
CapeBio	ZA
Capish Nordic AB	SE
Caravel Bio	US
CARBOGEN AMCIS	CH
Carterra	US
Casale	CH
Catalent Pharma Solutions	FR
Catalent Pharma Solutions GmbH	CH
Catalonia Trade & Investment	DE
Catalyze Switzerland GmbH	CH
Catenion	DE
CatSci	UK
CCRM	CA
CD4 Therapeutics	DE
CDR-Life AG	CH
CeGaT	DE
Celerion Switzerland AG	CH
Cell and Gene Therapy Catapult	UK
Cell Environment	FR
CELL-EASY	FR
Cellbox Labs	LV
Cellbox Solutions	DE
CellCarta Biosciences	BE
Collectricron AB	SE
Cellknit	KR
CELLnTEC Advanced Cell Systems	CH
Cellula Therapeutics SA	CH
Celonic AG	CH
Cencora - World Courier	ES
CENEXI	BE

Participating companies

Company	Country
Centerview Partners	US
Centre for Human Drug Research	NL
Centre for Process Innovation	UK
Centrix Pharma Solutions	UK
CER Groupe	BE
CERN	CH
Cetacea Clinical GmbH	CH
CÉZAME CONNEXIONS	FR
CGC	CH
Chain Peptides	FI
chAlron SA	CH
Charles River Laboratories	FR/DE
CheckImmune	DE
CheckOrphan	CH
ChemCon	DE
Chemelectiva Srl	IT
Chemestmed OÜ	EE
Chemengineering Switzerland AG	CH
ChemPartner	CN
ChemRar (Shaoying) Pharmaceutical Co., Ltd.	CN
CHEMSPACE	UA
Chengdu Kanghong Pharmaceutical Group	CN
Chief Medical Officer	DE
Children's Tumor Foundation	US
Chime Biologics	CH
Cilag International	CH
Cilcare	FR
Cioa SAS	FR
CinnaGen	IR
CIS Biopharma AG	CH
Cisema	CN
Citeline	UK
Citibank, N.A., Sioux Falls, Zurich Branch	CH
CK QLS	CH
CLARIO	CH/DE/US
Claudia Ulbrich Consulting	CH
Clean Cells	FR
CLEANGRAD D.O.O	SI

Company	Country
ClearieBio Therapeutics	CH
ClexBio AG	CH
Clinexel Life Sciences	IN
Clinigen Healthcare Switzerland Sarl	CH
Clinilabs	US
ClinOps Advisory Turner GmbH	CH
Clirecon ApS	DK
CLUSTER SIMI	ES
CM Fine Chemicals GmbH	CH
CMAX Clinical Research	AU
CMC & More GmbH	CH
CNRS	FR
COCOON BIOSCIENCE S.L	ES
Cogmotiv FlexCo	AT
Cognizant	IN
Cohesion Bureau, operated by BioConfidant Sarl	CH
Colab AccelBio Associação AccelBio	PT
Collaborative Drug Discovery	UK
Comac Medical	BG
Comser	ES
Concept Life Sciences	UK
Conectus	FR
Congress Hub Bern	CH
Connect2	CH
Conscio Holding GmbH	DE
Convex Phase I unit	BG
Cooley LLP	UK/US
Coopération Globale	CH
Copoly.ai	CA
CordenPharma	CH/DE
Coris BioConcept	BE
Council for Scientific and Industrial Research	ZA
CRA International (Switzerland) GmbH	CH
Cradle Switzerland AG	CH
CRIF	CH
CRITICA Pharmaceutical PC	GR
Cross Research SA	CH
Crossroads Consultancy & Services	CH

Participating companies

Company	Country
Crosswalk Therapeutics AG	CH
Crown Bioscience	NL
Crux Biolabs	AU
CSEM	CH
CSL	CH
CTC Resourcing Solutions AG	CH
Cube Biotech	DE
Cura Therapeutics	CA
CuraCell	SE
Curare Swiss AG	CH
Curatis Holding AG	CH
CureDiab Metabolic Research	DE
CureRoot	ZA
Curia Italy Srl	IT
Curie.Bio	US
CView-Consult	FR
Cybiome GmbH	CH
Cynbiose	FR
Cytel	DE
Cytion	DE
Cytiva Europe GmbH	CH
CZ Vaccines	ES
dabl	IE
DAIICHI SANKYO EUROPE	DE
Data Intelligence	CH
DataArt	DE/US
Datasite	CH
Davis Polk & Wardwell	US
De Bord International	CH
DEASYL SA	CH
Debiopharm International SA	CH
Deep MedChem a.s.	CZ
DeepLife	FR
delaware Germany	DE
Deloitte AG	CH
DELTA PHARMA-AL	AL
Demcon Life Sciences & Health Eindhoven B.V	NL
Department of Science, Technology and Innovation	ZA

Company	Country
DeSC Healthcare	JP
Development Center for Biotechnology	TW
DEVINTEC Sagl	CH
Dextral Solutions	AT
DHL Express (Switzerland)	CH
DIAMANTE Healthcare Consulting Sagl	CH
Diamics	DE
Diatheva S.R.L.	IT
Diex Recherche	CA
Dimericon Therapeutics AG	CH
Discovery Studio (part of Anacura)	BE
DKSH Schweiz AG	CH
DLRC	UK
Docuply UG	DE
Domainex	UK
Dottikon Exclusive Synthesis	CH
Double Helix Technologies SIA	LV
Dow	CH
Dr. Reddy's Laboratories	CH
DRUGABILIS	FR
DryLabz	CH
dsm-firmenich	CH
DTI-Tech	CH
Dutch Embassy	CH
dynamXIP	CH
EastMabBio	CN
Ecolab Schweiz	CH
Bern Economic Development Agency	CH
Economic and Trade Office, Spanish Embassy	CH
Economic Promotion Canton of Schaffhausen	CH
Economic Promotion Canton of Zug	CH
Economic Promotion Valais	CH
EDELRIE	FR
EdgeOne Venture Partners	US
EFAFLEX SWISS	CH
Eldian Biomed	CH
ELEKS SWITZERLAND	CH
Element Eleven	BE

Participating companies

Company	Country
eleva	DE
Elionova AG	CH
Elthera AG	CH
EM Ventures	CH
Embassy of Canada	CH
Embassy of Finland in Austria	AT
Embassy of Japan	CH
Embassy of Portugal	CH
Embassy of Slovenia	CH
Embassy of Switzerland in China	CN
Embassy of the Republic of South Africa	BE
Emblion Technologies SA	CH
EmVenio	NL
Enable Biotech AG	CH
Enamine	UA
Enantios AG	CH
Endok S.r.L	IT
Endpoints News	UK
Ensu GmbH	CH
enterprise ireland	CH
Enzene Inc.	US
EPFL	CH
EpiCure	DE
EpiDisease SL	ES
Epiquire AG	CH
EPO Experimental Pharmacology and Oncology	DE
Eppendorf SE	DE
EquipNet LTD	CH
EraCal Therapeutics Ltd	CH
ERBC GROUP	FR
Ernst & Young AG	CH
EsoCap AG	CH
Etablissement Français du Sang	FR
ETAP-LAB	FR
ETH Zurich	CH
Ethris	DE
ETOILE CAMEROUN "ETOICAM" SARL	CM
Eureka Network	BE

Company	Country
Euresearch	CH
Eurofins ADME BIOANALYSES	FR
Eurofins BioPharma Product Testing Switzerland	CH
Eurofins Discovery	DE
Eurofins Optimed	FR
Eurofins Professional Scientific Services	CH
Euromed Pharma	FR/IT
European Molecular Biology Laboratory (EMBL)	DE
eversyn	DE
Evestia Clinical	UK
Evidence Health Srl	IT/ES
Evitria AG	CH
EvlaBio AG	CH
Evogence Biologics Oy	FI
EVOLVE	AR
EVOMEDIS	AT
Evonik	DE
EVOTEC	DE/FR
ExcellGene SA	CH
Excelsior Biopharma	TW
Exeliom Biosciences	FR
Experimentica	FI/LT
Explicyte	FR
Eyam Health	CA
ezCaretech	KR
F. Hoffmann-La Roche AG	CH
FaaS Capital Switzerland	CH
FairJourney Bio	PT
Famar Health Care Services Madrid S.A.U	ES
Farinha Guedelha Executive Network Health	CH
Farma Mondo UAB	LT
Farmhispania Group	ES
FatiAbGen International GmbH	CH
FB Global Regulatory Consulting and Coaching	CH
Federal Department of Defense and Civil Protection	CH
Ferring International Center	CH
FGK Clinical Research	DE
FHNW School of Life Sciences	CH

Participating companies

Company	Country
Fidelio Healthcare Partners	DE
FirmCyte AG	CH
Finanz und Wirtschaft / Tamedia	CH
Firefinch Software	UK
Fischer PreclinTox Consulting	CH
FITODENTA	LT
Five Office	CH
Flanders Investment & Trade	FR
Flex Databases	CZ
floatz GmbH	CH
FloBiotech GmbH	CH
Flomics Biotech	ES
Florin Muraru	CH
FluoSphera SA	CH
FOCALIS	IT
Fold AI	AU
Foley & Lardner LLP	US
FONDATION SOPHIA ANTIPOLIS	FR
Fondazione del Piemonte per l'Oncologia	IT
Fongit	CH
Food Brewer	CH
Forbion	NL
Fördergesellschaft IZB mbH	DE
Fortrea	CH
Fortrea	ES/IN/DE
Forty51 Advisors AG	CH
FoRx Therapeutics AG	CH
Fractional CSO	CH
FrankfurtRheinMain	DE
Fraunhofer-ITEM	DE
Fresenius Kabi	CH
freshcom	CH
Fribourg Development Agency	CH
Frontage Europe S.r.l	IT
Fuchs Patentanwälte Partnerschaft mbB	DE
Fundess	DE
Fusix Biotech	DE
FUST Lab	KR

Company	Country
Future Health Pharma GmbH	CH
futureSAX	DE
Fy Cappa Biologics AG	CH
FyoniBio	DE
G-Med Consulting	CN
Gabather AB	SE
GaeaOU	EE
Galapagos	CH
Galileo Research	IT
Galser SA	CH
Ganda Business Solutions AG	CH
GBiotech Sàrl	CH
GemPharmatech	CN/US
GenAlz	CA
Genedata AG	CH
Genentech	US
Genesupport SA	CH
Genevant Sciences GmbH	CH
Genevovager	CN
Genius Search	DE
Genolier Innovation Hub	CH
Genomics	UK
Genomill Health	FI
genOway	FR
GenScript Biotech (Netherlands) B.V	NL
GenSearch Switzerland	CH
GenSensor	FR
Gerresheimer	DE
GETEC PARK.SWISS	CH
Getinge Deutschland	DE
Giblot Food and Health	CH
Gilles Chatelin	CH
GlassMedical ai Schweiz GmbH	CH
GliaPharm SA	CH
GlintMed Innovation	TW
GlioCART GmbH	CH
Global Data	UK
GlobalData Media	UK

Participating companies

Company	Country
Glycanostics	SK
GlycoEra AG	CH
GlycoThera Analytics	DE
GlyProVac	DK
gMendel	DK
GMP Bridge	CH
GMP-Verlag Peither	DE
GMP4U GmbH	CH
Gnosis Bioresearch	CH
GO-Pen ApS	DK
Gouya Insights & KG	AT
Graphene Square Chemical	KR
Greater Geneva Bern area	CH
Greater Zurich Area	CH
Greaves Brewster LLP	UK
GROUPE PRODUCTLIFE	ES/FR
Grünenthal	DE
GSMN Swiss Medical Network	CH
GT Gain Therapeutics SA	CH
Gubra	DK
Gubra	CH
HAMILTON BONADUZ	CH
Harmony Clinical Research BV	BE
Haute Ecole Arc Ingénierie	CH
Haya Therapeutics SA	CH
HBC HeppBiotechConsulting	CH
HBM Partners AG	CH
HDI Global SE	CH/DE
Health and Life Sciences Cluster	BG
Health Cluster Portugal	PT
Health Holland	NL
HealthCare Royalty	US
Healthecon AG	CH
HealthSeed	CH
Heidelberger & Partners GmbH	CH
Heidrick & Struggles	CH
HekeTiss SA	CH
Helical	LU

Company	Country
HELLENIC BIOCLUSTER	GR
Helmes AS	EE
Hemastatx GmbH	CH
HEMEX (Switzerland) AG	CH
Herman & partnerji SK, d.o.o	SI
HES-SO Valais-Wallis	CH
Hesyra-Medical GmbH	CH
Hettich AG	CH
High Force Research	UK
Hippocrates Research Swiss SA	CH
Hoffmann & Partner AG	CH
Homax Advisory Sarl	CH
Homburger AG	CH
House of Lab Science AG	CH
HTCR-Services	DE
HUB Organoids B.V	NL
Human.technology Styria	AT
Humanitas Research Hospital	CH
Humion	CH
Hungarian Biotechnology Association	HU
Hüstebeck	DE
hVIVO	UK
Hybrigenics Services	FR
iBody	JP
ICE Bioscience	CN/US
ICEX ESPAÑA EXPORTACION E INVERSIONES	ES
ICON Clinical Research (Switzerland) GmbH	CH
ICON Clinical Research España SL	ES
Icosagen	EE
ICTA	FR
IDDI	BE
IDEXX Bioanalytics	DE
Idiomatic Bio	DK
IDT Biologika	DE
Igaidi AS	NO
iGii (a trading name of Integrated Graphene)	UK
IHMA Europe	CH
Iktos	FR

Participating companies

Company	Country
IL-CSM Clinical Supplies Management	DE
ILIAS Biologics	KR
iLife Consulting	BG
ILLUMINA	CH
Imapac	UK
Immitra Bio GmbH	CH
ImmuneWatch	BE
ImmunoOs Therapeutics AG	CH
IMP	DE
IMPAG AG	CH
Impingo Sarl	CH
In Virtuo Laboratories SA	CH
InClino s.r.o	CZ
Incyte Biosciences International Sàrl	CH
Industrial Research Assistance Program (IRAP)	CA
Inferre Consulting	CH
Informa	DE/UK
infoteam Software	CH
Ingenza	UK
INTS SMO	FR
INK Global	CA
Inkocell	CH
InkVivo Technologies AG	CH
INNEXIS Holding & . KG	DE
InnoCore Pharmaceuticals	NL
Innosiamo AG	CH
Innosuisse	CH
Innovationsförderung, AWA, Kanton BS	CH
Innovaud	CH
INOFEA AG	CH
Inotiv	DE/US
Inoviem Scientific SAS	FR
Inovotion	FR
Inpharmatis SIA	LV
Inqaba Biotechnical Industries (Pty)	ZA
inscreenex	DE
InsideReg Sarl	CH
Insilico Medicine	US

Company	Country
InSilicoTrials	IT
InSphero AG	CH
Institute of Life Sciences, HES-SO Valais	CH
Institute of oncology research	CH
Integra Biosciences AG	CH
IntegraGen	FR
InterAx Biotech AG	CH
International Market Access Consulting	CH
InTheKnow PharmaSolutions	CA
Intralink	UK
Inven2	NO
Inventicia GmbH	CH
Invest & Trade Western Australia	UK
Invest Hong Kong	CN
Invest in Bavaria	DE
Invest in Skåne	SE
Invest Lithuania	LT
Invest Region Leipzig	DE
Investissement Québec	CA
Investment and Development Agency of Latvia	LV
iOMEDICO	DE
iOrganBio	US
IPRATECH	BE
IPS Biopharma AG	CH
iPsomics	NL
iQone Healthcare Switzerland SA	CH
IQVIA AG	CH/UK/DE
IR Innovate Research Pvt	IN
IRBM	IT
IRCCS Centro Cardiologico Monzino	Italy
Iris Biotech	DE
Iron Bridge	DE
ISIS IC GmbH	DE
ISOREA AB	SE
Isospec Analytics SA	CH
Italian Consulate in Zurich	CH
ITOCHU Europe PLC	UK
ITR Laboratories	CA

Participating companies

Company	Country
IWATA LABEL Europe	DE
JAFRAL d.o.o	SI
Jantar GmbH	CH
Japan External Trade Organization	JP/CH
Jeffries IP	CH
Jericho Sciences	US
JETEMA	KR
JFG Life Sciences Stiftung der Universität Basel	CH
Jiuzhou Pharmaceutical	DE
Johnson & Johnson	CH
Jones Lang LaSalle SE	DE
Julius Clinical	NL
Just-Evotec Biologics	UK
Justin Stindt Consulting AG	CH
Juvion Health Sciences SA	CH
K-Recruiting Schweiz	CH
k2p PharmaCon	DE
KACTUS	US
Kahimmune Therapeutics	FR
Kanghong Pharmaceutical Group	CN
Kanton Aargau, Standortförderung	CH
Kapadi	US
Kapelan Bio-Imaging	DE
Katana Labs	DE
KATZAROV S.A. - Patent & Trademark Attorneys	CH
Kaye - Subsidiary of Amphenol	DE
KBI Biopharma SA	CH
KCAS Bio	FR
Kemwell Biopharma Pvt	IN
KennedyFitch (KF) AG	CH
KERRY	IE
KHANU Fondsverwaltung	DE
KIMALYS	FR
KinSea Lead Discovery AS	NO
KINSY	ES
Kisco Sarl	CH
Kissei America	US
Kistemaker Pharma Consultancy B.V	NL

Company	Country
Klaster LifeScience Krakow Foundation	PL
Knowbio	DE
Komtur Pharmaceuticals e.K	DE
Konexio Biotech S.L	ES
KOTRA Zuerich	CH
Kowa Pharmaceutical Europe AG	CH
KPMG AG	CH
KreaMedica	CA
Kriphonte Therapeutics	DK
KriSan Biotech	TW
KVALITO AG	CH
Kymanox Corporation	US
Kyirin Pharmaceutical	DE
L-BASE	KR
LabConnect	CH/DE
Labcorp Central Laboratory Services Sarl	CH/FR/UK/US
Labena	SI
Labor LS SE & . KG	DE
Laboratoire CEVIDRA	FR
Lamprecht Pharma Logistics	CH
Landmark BioVentures AG	CH
Latvian Council of Science	LV
Latvian Institute of Organic Synthesis	LV
Latvijas Universitāte (University of Latvia)	LV
Lausanne University Hospital	CH
Lead Discovery Center	DE
leadXpro AG	CH
Leanbio, S.L	ES
Lederer & Partner AG	CH
LEGIAPARK S.A	BE
Leica Microsystems (Schweiz)	CH
Leman Biotech Lausanne SA	CH
Lemna Bio SA	CH
leon-nanodrugs GmbH	DE
Leukocare	DE
LFB Biomanufacturing	FR
LGC Standards	IT

Participating companies

Company	Country
Liage Benelux BV	NL
Libera Bio S.L	ES
Lichtsteiner Foundation	CH
LIDE Biotech	CN
Life Science Cares Switzerland	CH
Life Science Nord	DE
Life Science Zentrum Mainz	DE
Life Science Zurich Young Scientist Network	CH
Life Sciences Real Estate Limited	IE
LifeSci Advisors	CH
Lifesome Therapeutics	ES
Lilly Deutschland	DE
LimmaTech Biologics AG	CH
Limula SA	CH
Linear Clinical Research	AU
LINK Medical	FI/NO
Linkster Therapeutics AG	CH
LINNEA	CH
LIQID Medical	ZA
LISAvienna	AT
LithuaniaBIO	LT
Liviovea GmbH	CH
Longenesis	LV
Lonza AG	CH/UK
LoopLab Bio	AT
Losan Pharma	DE
LOTRI Metrology	SI
LOTTE Holdings	JP
LSCN	DE
LTZ Therapeutics	CN/DE
LubioScience GmbH	CH
Lucerne University of AS	CH
LUCID Analytics AG	CH
Lucideon Group	UK
Ludwig Institute for Cancer Research	CH
Luko laboratorija MB	LT
Luminance Health AG	CH

Company	Country
Lumis International	DE
Lupin Manufacturing Solutions	UK
Luzsana Biotechnology Europe	CH
LxBio Pharmaceuticals	PT
M&G Advisors	CH
MabDesign	FR
Mabion S.A	PL
Macrogen Europe GmbH	CH
Madrigal Pharmaceuticals	CH
Magma Science	PT
MAI CDMO S.L	ES
Mangisa Clinical Solution	CH
marcommotion	DE
Margon Management B.V.	NL
MARTI FARM d.o.o	HR
Maruho	JP
Matilda Cepele	AL
Matrixorne	JP
Maxia Strategies GmbH	CH
Mayo Clinic	US
mBioPharmaConsulting SAS	FR
MBM Future Health	DE
McArthur and Associates GmbH	CH
MCE CARREL	FR
MDTB Cell Manufacturing	DE
MEExpansion Sàrl	CH
Median Technologies	FR
MEDIC LABOR	SK
Medical Research Council Laboratory	UK
Medical University of Vienna	AT
Medicilon	CH/SE
Medicines Discovery Catapult	UK
Medicon Valley Alliance	DK
Medicover Integrated Clinical Services	RO
Medidata Solutions	UK
MEDIS	SI
Medistri SA	CH

Participating companies

Company	Country
Medpace	US
MEDTECH INNOVATION ON ADVANCED MEDICINE	ES
Medvisis Switzerland AG	CH
MedXCell SA	CH
Melius Organics SL	ES
Memo Therapeutics AG	CH
Menarini Biotech	IT
Merck KGaA	DE
Merck Serono	UK
Meru Advisors	US
metaLead Therapeutics AG	CH
MethylX	CH
MetricPharm AG	CH
Metromol SA	CH
Metronik d.o.o	SI
Metronomia Clinical Research	DE
MetyS Pharmaceuticals AG	CH
Microcity SA	CH
Microsynth AG	CH
Midas Pharma	DE
Mikron Automation	CH
Miltenyi Biotec Swiss AG	CH
MIMETAS	NL
Minakem CDMO	FR
Minaris Advanced Therapies	DE
Ministerium für Wirtschaft, Rheinland-Pfalz	DE
Ministry of Foreign Affairs of Estonia	EE
Miramoon Pharma	ES
Mirava Bio Sarl	CH
Mirum Pharmaceuticals AG	CH
MITOLOGICS	FR
MLM Medical Labs	DE
MNDL BIO	IL
Mo:re	DE
ModelMole	UK
Modulari-T	CA
Molecular Forecaster	CA

Company	Country
Molecular Health	DE
Molecular Partners AG	CH
Monte Rosa Therapeutics AG	CH
Moon Pharma	US
MosaMatrix	NL
Moss Bio	KR
Movatype Biomaterials	CH
Move Venture Consulting	CA
MRGN Advisors Sarl	CH
MSD	UK
MTTlab srl	IT
MUGENBIO	CH
MUNIT	CH
Murata Electronics Europe B.V	NL
MutaDent	CH
MUVON Therapeutics AG	CH
MV BioTherapeutics SA	CH
MyAmici	UK
Mycenax Biotech	TW
Myllia Biotechnology	AT
Myonex	FR
MyoPax	DE
Myria Biosciences	CH
Naexture Research Sagl	CH
Nanolynx Biologics AG	CH
Nanopharm	UK
NanoTemper Technologies	DE
NanoZyme University of Basel	CH
Nathalie Jenni Consulting GmbH	CH
National Pharmaceutical Industries	OM
National Research Council Canada	CA
Navigo Proteins	DE
NAYA LIFE SCIENCES d.o.o	SI
NBE-Therapeutics AG	CH
Ncardia	NL
Neocarbons SA	CH
Nerai Bioscience	CH

Participating companies

Company	Country
Ness Therapeutics	CA
Netherlands Enterprise Agency	NL
Netherlands Innovation Network	DE
Neuland Laboratories	CH
Neurimmune AG	CH
Neuro-Sys	FR/US
Neuroinnovation Ltda	CL
Neurometa Therapeutics	SE
New England Biolabs	DE
New Life Biopharma Limited	IE
NewBiologix SA	CH
Newcelex	CH
NexMR AG	CH
Nextech Invest	CH
nextImpact	CH
Nikon Europe B.V.	CH
NL Embassy	CH
nNano	CH
NNIT UK	UK
Noema Pharma AG	CH
Nordic Innovators P/S	DK
North Carolina Life Sciences Organization	US
Northway Biotech	LT
NorthX biologics	SE
Nouscom AG	CH
NovaGo Therapeutics AG	CH
Novalix	FR
Novartis Pharma AG	CH
Novo Holdings	DK
Novo Nordisk	CH
Novotech	AU
NRW.Global Business	DE
NTT DATA	IT
Nucelion Therapeutics	IN
Nucleate Switzerland	CH
Nucleus Network Ltd	UK
Nuclidium	CH

Company	Country
Numab Therapeutics AG	CH
Numaferm	DE
numaH	CH
Nuvisan	DE
Nxera Pharma Co., Ltd., Tokyo, Basel Branch	CH
NXI Therapeutics AG	CH
ObelysQ SA	CH
Oculus Holding AG	CH
OenoHealth	CH
OHMX.bio (part of Anacura)	BE
Olgram SA	CH
oloBion SL	ES
Olon SpA	IT
OMNI Life Science GmbH	CH
Oncodesign Services	FR
Oncology Research Expertise	FR
Oncosyne	NO
OneBio Innovation Centre	ZA
ONESOFTDIGM	KR
Oniria Therapeutics	ES
Ono Pharmaceutical	UK
Ontrack Biomedical AG	CH
Onward Therapeutics SA	CH
Ornyx Scientific	UK
Open Protein AI	SG
Ophthalmopro	DE
OPIS s.r.l	IT
Opterion Health AG	CH
Optima pharma	DE
OptoLumina AG	CH
Oregon Health & Science University	US
Oregon Life Sciences	US
Oregon State University	US
Oriente SA	CH
Orion Biotechnology Switzerland	CH
Ortho-Design PTY	ZA
Oryl Photonics SA	CH

Participating companies

Company	Country
Oslo University Hospital and University of Oslo	NO
Österreichische Wirtschaftsdelegation für CH	CH
Outlook Therapeutics	CH
Oxeltis	FR
Oxford Nanopore Technologies plc	UK
P4 precision medicine	UK
palleos healthcare	DE
Panome Bio	US
Parexel	US
Parithera SA	CH
Partex.AI Labs	DE
Paspigioni	UK
PatrickToxConsulting	FR
PCI Pharma Services	US/UK
PDC Therapeutics SA	CH
Pensatech Pharma	DE
PerfeTTO Network	IT
Permanent Mission of Estonia to the UN Office	CH
Perseo Pharma AG	CH
Pestalozzi Attorneys at Law	CH
Pharma Consulting ENABLE GmbH	CH
Pharma Excipients International	CH
Pharma Holdings AS	NO
PharmaBiome AG	CH
PharmaBlock Sciences (Switzerland) AG	CH
PharmaCamp	CH
PharmaKorell GmbH	CH
PharmAla Biotech	CA
PharmaLegacy Laboratories (Shanghai)	CN
PHARMALEX	FR
PharMarketing GDPR Life Sciences	FR
Pharmaron, Inc.	UK
Pharmassist	GR
Pharmacube Group	CN
Pharmidex	UK
PharmInsight	CH
Pharmora	UK

Company	Country
Pharvaris GmbH	CH
PHC Ventures	CA
Phialogics	CH
Philip Morris Switzerland Sàrl	CH
PHINE Bio AG	CH
Phoenix CR	AE
PHT International Limited	US
PI Health Sciences	IN
Pictet Alternative Advisors	CH
PIMS Technology SAS	FR
Piramal Pharma Solutions	US
Pivot Park Exploitation BV	NL
PKNM Solutions Sàrl	CH
PLL Therapeutics	FR
PLX Healthcare Services (Schweiz) GmbH	CH
PME	CH
PMS Process Management System Sarl	CH
PMT - Pôle des microtechniques	FR
Pohang University of Science and Technology	KR
Pohang-City	KR
Polymaterials AG	DE
PolyPeptide Group	CH
PolyPeptide Group	SE/BE
Populus Bio Sàrl	CH
Porsolt	FR
Porton Pharmaceutical Chemicals GmbH	CH
POE (Suisse) Sagl	CH
Præd Pharmaceuticals Ltd	CH
PRC Comunicare la Scienza	CH
PreciMUNE - UNIL/CHUV spin-off	CH
Precise Health SA	CH
Precision for Medicine	UK
Preclina	KR
Premier Research	US
Prevision Medicine AG	CH
Priavid	DE
PRIME - University of Toronto	CA

Participating companies

Company	Country
Prinsus Spin-off Company	GR
PRIOT d.o.o	SI
Probio Technology BV	NL
ProBioGen	DE
Procam Videoproductions	CH
Procavea Biotech AG	CH
ProJect Pharmaceuticals GmbH	DE
Promega AG	CH
PROMOS	IT
Protect Animal Health	TW
Proteintech	UK
ProteoGenix	FR
Proteros biostructures	DE
ProVasctec	IE
Provectis Healthcare AG	CH
PSG Dover	DE
PSI CRO AG	CH
PULSE developed by EPIC SUISSE SA	CH
Pureos Partners AG	CH
Q Close Solutions	CH
QBDC GmbH	CH
QIAGEN	DE
Qinos	CH
Qity	BE
QPS	NL
Quality Assistance	BE
Quantoom Biosciences	BE
QUASAR Therapeutics	DE
Quinn- The AI Scientist	US
QULLA	CH
Quotient Sciences	UK
QuirieGen B.V	NL
radiomics.bio	BE
Rados Recruiting	DE
Raffles Pharmatech	CN
Randox Laboratories	UK
Rapid Novor	CA
Rare Crew	SK
RC Tritec AG	CH

Company	Country
Reaction Biology Europe	DE
Real Chemistry	UK/US
Real Chemistry GmbH	CH
Recipharm Advanced Bio	PT
Regenera SA	CH
Reign One Capital	MN
Release Therapeutics SA	CH
REM Analytics SA	CH
RENTSCH PARTNER	CH
Rentschler Biopharma SE	DE
Repertoire Immune Medicines (Switzerland) AG	CH
REPROCELL EUROPE	UK
Research Council of Lithuania	LT
Research PIECES	FR
Resolian	UK
RespAct GmbH	CH
Reuters	CH
Revnuu GmbH	CH
Revity	CH/DE/FR/NL
Rezon Bio	PL
RIANA Therapeutics	AT
Richter BioLogics	DE
Risklick AG	CH
Rivia	CH
Robeauté	FR
Roche	DE
Roche Diagnostics France	FR
Rockstone Engineering Switzerland Sarl	CH
Rödl AG	CH
Rodon Biologics	PT
ROKIT HEALTHCARE	KR
Roland Berger	CH
Ropes & Gray	US
Roquette Health & Pharma Solutions	FR
Rothschild & Co	FR
Rottendorf Pharma	DE
RoukenBio	UK
Royalmount BioPharma Services	CA
Sagitta Biotech	BE

Participating companies

Company	Country
Sai Life Sciences	IN/US
Salipro Biotech	SE
Salvina Therapeutics AG	CH
Samsung Biologics	US
Santero Therapeutics	BE
Santhera Pharmaceuticals (Schweiz) AG	CH
Sanyou Biopharmaceuticals	CN
Sartorius Stedim Biotech	DE
Sartorius Stedim Switzerland AG	CH
Sartorius/Mattek	FR
SAS BOTdesign	FR
SATW	CH
SaxoCell	DE
Saxony Trade & Invest	DE
Scantox Denmark Aps	DK
Schedio SA	CH
Schrödinger	DE
scienceindustries	CH
ScienceValue Heidelberg (SVH)	DE
Sciensus	CH/UK
Scintial	NL
Sciento Technology	UK
Sciomics	DE
Scope International AG	DE
ScopeM ETH Zurich	CH
Scottish Development International	DE
Sealantium Medical	IL
Secoya Technologies	BE
Securecell AG	CH
Seda Pharmaceutical Development Services	UK
SEED Biosciences SA	CH
Seito Biologics AG	CH
Sekisui Chemical	JP
Selecta Biotech SE	SK
Selecxine	KR
Selfdiagnostics	EE
Selmod GmbH	CH
Selvita S.A	PL
Sen-Jam Pharmaceuticals	CH

Company	Country
Senn Resources AG	CH
Sens Vue ApS	DK
SENTV DMEDIA	SN
SEQALIS	BE
Seqens	FR
SeqVision	LT
SeraDiaLogistics	DE
SeraNovo B.V	NL
Service de l'Économie de Neuchatel	CH
Servier	FR
Servier Institute of Therapeutic Innovation	FR
Seventure Partners	FR
SFNV	CH
SG-PEC	FR
SGS	BE/ES/FR
SGS Analytics Switzerland AG	CH
SGS Life Sciences Geneva	CH
SGS Vitrology Limited	UK
ShamsAI	CH
Shape Biopharmaceuticals AG	CH
Shimadzu Schweiz GmbH	CH
Shuimu Biosciences	CN
SIA PrintyMed	LV
Sichuan Huiyu Pharmaceutical	CN
Sidrapex Pte	CH
SIEGFRIED DiNAMIQS AG	CH
sifin diagnostics	DE
Signal26 Biotherapeutics SA	CH
Simbec-Orion	UK
Simbionte EE	ES
Simcere UK	UK
Sinfonie LSM GmbH	DE
Single Cell Discoveries B.V	NL
sitem-insel	CH
SIX Swiss Exchange	CH
SK pharmteco	US
SKC BERATUNGSGESELLSCHAFT MBH	DE
Skills Alliance	CH/UK
SKM-IP Patentanwälte	DE

Participating companies

Company	Country
Skyvor Medical AG	CH
SLAS	US
Slope	US
Slovak Investment and Trade Development Agency	SK
Slovenia Biotech Hills	SI
SMALTIS	FR
Smart	BE
Socorex Isba SA	CH
Sodha Pharma Consulting	CH
Sofinnova Partners	FR
Softmining Srl	IT
Sokol Bioconsulting	CH
SOLBEX GmbH	CH
Solid State Pharma	CA
Solothurn Economic Promotion Agency	CH
Solvias AG	CH/US
Sony AI	CH
Sotio Biotech AG	CH
SP Clinical Consulting	CH
Space Pharmaceuticals AG	CH
Spanish Bioindustry Association - AseBio	ES
Sphinx Scientific Laboratory	CN
SPILLO di Alessandro Di Domizio	CH
SPIRIT Slovenia	SI
Springer Nature	UK
SRF	CH
SSI Strategy	SE
STA Strategic Transactions Advisory	CH
Staburo	DE
Stada Arzneimittel	DE
Stagebio	DE
Stämm Vegh SA	CH
Startupticker.ch	CH
State Government of Victoria	FR
STATE RESEARCH INSTITUTE FOR MEDICINE	LT
steerBIO GmbH	CH
StellarPeakSystems	CA
Stellenbosch University	ZA
STEMCELL Technologies	CA/CH

Company	Country
Step Pharma	FR
Sterling Pharma Solutions	UK
Stifel Europe Limited	FR
Stiftung grow	CH
SUCCIPRO	ES
Summa Biotech B.V	NL
SunRegen Healthcare AG	CH
SunRock Biopharma S.L	ES
Superlab Suisse AG	CH
Supply Chain Operations SA	CH
SUPSI/DTI	CH
Sussex Research Laboratories	CA
Suzhou Auxin Bio-Pharmaceuticals	CN
Svar Life Science AB	SE
Swarm Oncology	UK
SwedenBIO	SE
Swiss Biotech Association	CH
Swiss Biotech Center SA	CH
Swiss Broadcasting Corporation (swissinfo)	CH
Swiss Business Hub China	CN/IN
Swiss Business Hub France	FR
Swiss Business Hub Japan	JP
Swiss Business Hub Korea	KR
Swiss Business Hub UK	UK
Swiss Cancer Institute	CH
Swiss Clinical Trial Organisation	CH
Swiss Consultant-Network GmbH	CH
Swiss Federal Institute of Intellectual Property	CH
Swiss Health Angels	CH
Swiss Life	CH
Swiss Medical Network	CH
Swiss Nuclear Forum	CH
Swiss Rockets AG	CH
SwissHikes with Yoga	CH
Swissmedic	CH
Swissnex	CH
SwissTech	SK
SwitchKine AG	CH
Switzerland Convention & Incentive Bureau	DE

Participating companies

Company	Country
Switzerland Global Enterprise	CH
Switzerland Innovation	CH
Switzerland Innovation Park Biel/Bienne	CH
Swizzard Pharma AG	CH
Sygnature Discovery	UK
Symcel AB	SE
Synameta Therapeutics Sarl	CH
SynapCell SAS	FR
Synendos Therapeutics AG	CH
Syneos Health Switzerland GmbH	CH
Synexa Life Sciences	UK
SYNGULON	BE
Synovo	DE
SYNSMART RASAYAN RESEARCH	IN
Syspro Automation	ES
Syspro Automation AG	CH
Systemisches Institut für Führung und Beratung	DE
T-Oncology AG	CH
T-ONE Therapeutics	IT
T3 Pharmaceuticals AG	CH
Tada Labs	DE
Taisho Pharmaceutical	JP
Taiwan Bio Industry Organization	TW
Tak BioSuisse	CH
Talisto GmbH	CH
Tandem Therapeutics AG	CH
Tane AG	CH
Tanner Pharma	US
TargetEx	HU
Taros Chemicals	DE
Tartu Biotechnology Park	EE
TBD Pharmatech	EE
Tecan	CH
Tech Edge Management	DE
Technology Innovation Agency of South Africa	ZA
TECregen AG	CH
Teguar	CH/US
Telemedicine Technologies Belgium	BE
Tempus AI	US

Company	Country
ten23 health AG	CH
Tenpoint Therapeutics GmbH	CH
Terra Quantum	DE
Tetra Pak Processing Systems	SE
Tetrakit Technologies	DK
TFS HealthScience	SE
The Coulter Partnership Sarl	CH
The Cultured Hub	CH
The Life Science Cluster	NO
The National Research Council of Canada	CA
therainnova AG	CH
TheraPPI Bioscience SA	CH
Thermo Fisher Life Technologies Europe B.V.	CH
Thermo Fisher Scientific Biologics Lengnau	CH/ES/NL/US
TIBIO Sagl	CH
Tigermud Swiss AG	CH
Tillotts Pharma	CH
TILT Lifesciences / Zug Pharma Group	CH
TissueLabs SA	CH
TO Therapeutics AG	CH
TokaBio (Pty)	ZA
TOLREMO therapeutics AG	CH
TOP MIDDLE L.L.C	AE
Topadur Pharma AG	CH
Torrey Pines Investment	US
Tox Consult Basel	CH
ToxStrategies, a BlueRidge Life Sciences Company	US
TPM, Science & Technology Park for Medicine	IT
TraceLine Solutions GmbH	CH
TRACER Europe BV	NL
TRAFIK Productions	UK
Transcell Biologics	IN
TransCrip Group Limited	UK
TransCure bioServices	FR
Transformiq	CH
TransHeps AG	CH
Translation-X	CH
TransPerfect	US
Transpharmation	CA

Participating companies

Company	Country
Trasis	BE
Trialize AG	CH
Trillome GmbH	CH
Trockle Consultancy	CH
Trophic Communications	DE
TrustSEC Sp. z o.o	PL
TS Kommunikation	CH
TUNECT CRO	AM
Turbine	UK
TwinEdge Bioscience SA	CH
Twist Bioscience	NL
UAB Biotecha	LT
UBS Switzerland	CH
UCB Farchim SA/UCB Pharma AG	CH
UCLouvain	BE
UFRJ	CH
Ultimate Medicine AG	CH
ULTRACE DEVELOPMENT PARTNER	FR
Umlaut.bio GmbH	CH
Unchained Labs	UK/US
Uni Wuerzburg - TTO	DE
Unilabs A/S	DK
Università degli Studi di Torino	IT
Università della Svizzera italiana	CH
Université de Namur	BE
Université libre de Bruxelles	BE
University Hospital Zurich	CH
University Medical Center Freiburg	DE
University of Applied Sciences Western Switzerland	CH
University of Basel	CH
University of Bern	CH
University of Bristol	UK
University of Cambridge	UK
University of Coimbra	PT
University Of Exeter	UK
University of Fribourg	CH
University of Geneva	CH
University of Helsinki / Superbase Solutions	FI

Company	Country
University of Latvia	LV
University of Lausanne	CH
University of Nottingham	UK
University of Oxford	UK
University of Pisa	IT
University of Zurich	CH
UNOMR	CH
Upperton Pharma Solutions	UK
V2O Consulting	BE
Vaccentis AG	CH
Vactech Oy	FI
Valanx Biotech	AT
Valur Management Group	CH
Vandria SA	CH
VebeGo AG	CH
VectioPep	EE
VectorBuilder	US
Velalabs GmbH	AT
Venture Valuation VV AG	CH
VentureCapital Magazin	DE
Venturelab	CH
Veranova	UK
VERAXA Biotech	DE
Veristat	US
Veritas In Silico	JP
Vernalis (R&D) Limited	UK
Versant Ventures	CH
Versarys Bioscience	CH
Vetter	DE
Vi Partners	CH
Viedoc	SE
WLS Switzerland GmbH	CH
Vincere Life Sciences LTDA	BR
Viopas Venture Consulting GmbH	CH
vips	CH
Vir Biotechnology, Inc.	CH
VirdisGroup Sàrl	CH
Virella	LI

Participating companies

Company	Country
ViroCarb	CA
Virusure Forschung und Entwicklung	AT
VISCHER AG	CH
Visienco	CH
Vivara Life Sciences	DE
VivoArchitect Sarl	CH
Vogel BioC	CH
Voisin Consulting CH Sarl	CH
Vossius & Partner	CH
VoxCell	CA
VTU Engineering Schweiz AG	CH
VUGENE	LT
Wacker Biotech B.V	NL
Walter Suisse SA	CH
Waters Corporation	US
Waters nv	BE
Wave Immune	FR
Wellington Partners LS VC	DE
Wemedoo AG	CH
WEP Clinical	UK
Wespi & Partner	CH
Wessence Language Lab	AR
West Pharma Services	IE
WExecutive	CH
White Raven	BE
Wiebecke Consulting	CH
Willuhn Consulting AB	SE
Windward Bio AG	CH
Witt/Kieffer Schweiz AG	CH
WittKieffer	FR
Worldwide Clinical Trials	UK
WuXi AppTec	CH/UK
WuXi Biologics	CN/DE
WuXi XDC	CN
Wyss Zurich Foundation	CH
XCubeBio AG	CH
Xemperia SA	CH
XenTech	FR

Company	Country
XGEN Venture SGR S.p.A.	IT
Xilis	NL
Xlife Sciences AG	CH
XtalPI Technology	CN/US
Yaohai Biotechnology Beijing	CN
Ymmunobio AG	CH
Yokogawa Deutschland	DE
Yokogawa Innovation Switzerland GmbH	CH
Ypso Facto Luxembourg S.A.	LU
YUMA Capital Partners	CH
YUMAB	DE
Zai Lab	US
Zasya Life Sciences	IN
Zenas Biopharma	US
Zenith-Tx	CH
ZentriForce Pharma Research	DE
Zeta CH AG	CH
Zeyu Capital	CH
Zhejiang Ausun Pharmaceutical	CN
Zuger Capital AG	CH
ZugPharmaGroup	CH
Zuhlke	DE
Zühlke Engineering	CH
Zurich University of Applied Sciences ZHAW	CH
ZuriEV	CH
ZüriPharm	CH
Zust-AI d.o.o	SI

Sponsors, exhibitors & partners

Main sponsors



Sponsors



Sponsors, exhibitors & partners



Supporting partners



Media partners



Host and event manager



Logistics and marketing partner



Save the date!

SWISS BIOTECH DAY 2027

April 26-27, 2027
Congress Center Basel

Are you interested in increased visibility at the next Swiss Biotech Day?

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!
Meet our team today at the help desk
or contact us at info@swissbiotechday.ch.



Sign in on our website at
swissbiotechday.ch
and stay updated about any news.

Host & event manager:



Logistics & marketing partner:

bamconn